WO2003088748A1 - Use of heme oxygenase-1 and products of heme degradation - Google Patents
Use of heme oxygenase-1 and products of heme degradation Download PDFInfo
- Publication number
- WO2003088748A1 WO2003088748A1 PCT/US2003/011411 US0311411W WO03088748A1 WO 2003088748 A1 WO2003088748 A1 WO 2003088748A1 US 0311411 W US0311411 W US 0311411W WO 03088748 A1 WO03088748 A1 WO 03088748A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- patient
- administering
- ferritin
- pharmaceutical composition
- organ
- Prior art date
Links
- 102000002737 Heme Oxygenase-1 Human genes 0.000 title abstract description 128
- 108010018924 Heme Oxygenase-1 Proteins 0.000 title abstract description 128
- 150000003278 haem Chemical class 0.000 title abstract description 24
- 230000015556 catabolic process Effects 0.000 title description 9
- 238000006731 degradation reaction Methods 0.000 title description 9
- 238000011282 treatment Methods 0.000 claims abstract description 154
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 41
- 208000035475 disorder Diseases 0.000 claims abstract description 27
- QBUVFDKTZJNUPP-UHFFFAOYSA-N biliverdin-IXalpha Natural products N1C(=O)C(C)=C(C=C)C1=CC1=C(C)C(CCC(O)=O)=C(C=C2C(=C(C)C(C=C3C(=C(C=C)C(=O)N3)C)=N2)CCC(O)=O)N1 QBUVFDKTZJNUPP-UHFFFAOYSA-N 0.000 claims description 196
- GWZYPXHJIZCRAJ-UHFFFAOYSA-N Biliverdin Natural products CC1=C(C=C)C(=C/C2=NC(=Cc3[nH]c(C=C/4NC(=O)C(=C4C)C=C)c(C)c3CCC(=O)O)C(=C2C)CCC(=O)O)NC1=O GWZYPXHJIZCRAJ-UHFFFAOYSA-N 0.000 claims description 195
- 238000000034 method Methods 0.000 claims description 160
- 239000008194 pharmaceutical composition Substances 0.000 claims description 127
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 claims description 123
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 123
- 210000000056 organ Anatomy 0.000 claims description 110
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 claims description 106
- 102000008857 Ferritin Human genes 0.000 claims description 89
- 238000008416 Ferritin Methods 0.000 claims description 88
- 230000000694 effects Effects 0.000 claims description 74
- 108050000784 Ferritin Proteins 0.000 claims description 73
- 108010002084 Apoferritins Proteins 0.000 claims description 62
- 238000002054 transplantation Methods 0.000 claims description 62
- 102000000546 Apoferritins Human genes 0.000 claims description 59
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 58
- 230000001939 inductive effect Effects 0.000 claims description 48
- 210000004185 liver Anatomy 0.000 claims description 46
- 230000004083 survival effect Effects 0.000 claims description 45
- 206010061218 Inflammation Diseases 0.000 claims description 35
- 230000004054 inflammatory process Effects 0.000 claims description 34
- 229910052742 iron Inorganic materials 0.000 claims description 29
- MVZXTUSAYBWAAM-UHFFFAOYSA-N iron;sulfuric acid Chemical compound [Fe].OS(O)(=O)=O MVZXTUSAYBWAAM-UHFFFAOYSA-N 0.000 claims description 26
- 208000028867 ischemia Diseases 0.000 claims description 26
- -1 desferoxamine Chemical compound 0.000 claims description 23
- 210000002216 heart Anatomy 0.000 claims description 21
- VBIZUNYMJSPHBH-OQLLNIDSSA-N salinazid Chemical compound OC1=CC=CC=C1\C=N\NC(=O)C1=CC=NC=C1 VBIZUNYMJSPHBH-OQLLNIDSSA-N 0.000 claims description 20
- 229950007671 salinazid Drugs 0.000 claims description 20
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 19
- 238000002399 angioplasty Methods 0.000 claims description 16
- 210000004072 lung Anatomy 0.000 claims description 15
- 210000003734 kidney Anatomy 0.000 claims description 14
- 230000002062 proliferating effect Effects 0.000 claims description 14
- 230000001413 cellular effect Effects 0.000 claims description 12
- 206010063837 Reperfusion injury Diseases 0.000 claims description 11
- 230000001684 chronic effect Effects 0.000 claims description 9
- 208000010227 enterocolitis Diseases 0.000 claims description 9
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims description 9
- 210000000952 spleen Anatomy 0.000 claims description 9
- 238000007631 vascular surgery Methods 0.000 claims description 9
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 230000002685 pulmonary effect Effects 0.000 claims description 7
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 6
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 5
- 206010019799 Hepatitis viral Diseases 0.000 claims description 5
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 5
- 206010040070 Septic Shock Diseases 0.000 claims description 5
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 5
- 230000004968 inflammatory condition Effects 0.000 claims description 5
- 210000003491 skin Anatomy 0.000 claims description 5
- 201000001862 viral hepatitis Diseases 0.000 claims description 5
- 230000029663 wound healing Effects 0.000 claims description 5
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 4
- 206010051606 Necrotising colitis Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 210000004556 brain Anatomy 0.000 claims description 4
- 208000004995 necrotizing enterocolitis Diseases 0.000 claims description 4
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 claims description 4
- 230000005855 radiation Effects 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 206010001986 Amoebic dysentery Diseases 0.000 claims description 3
- 206010002199 Anaphylactic shock Diseases 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 208000004429 Bacillary Dysentery Diseases 0.000 claims description 3
- 241000589876 Campylobacter Species 0.000 claims description 3
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 206010009895 Colitis ischaemic Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 206010014561 Emphysema Diseases 0.000 claims description 3
- 241000498255 Enterobius vermicularis Species 0.000 claims description 3
- 206010016654 Fibrosis Diseases 0.000 claims description 3
- 206010017915 Gastroenteritis shigella Diseases 0.000 claims description 3
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 3
- 208000032456 Hemorrhagic Shock Diseases 0.000 claims description 3
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 3
- 206010049771 Shock haemorrhagic Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 241000607734 Yersinia <bacteria> Species 0.000 claims description 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 3
- 208000003455 anaphylaxis Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 230000007882 cirrhosis Effects 0.000 claims description 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 3
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 claims description 3
- 208000008384 ileus Diseases 0.000 claims description 3
- 208000027138 indeterminate colitis Diseases 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 201000004409 schistosomiasis Diseases 0.000 claims description 3
- 201000005113 shigellosis Diseases 0.000 claims description 3
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 claims description 2
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 claims description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 2
- 230000002950 deficient Effects 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 230000002008 hemorrhagic effect Effects 0.000 claims description 2
- 201000008312 primary pulmonary hypertension Diseases 0.000 claims description 2
- RCNSAJSGRJSBKK-NSQVQWHSSA-N Biliverdin IX Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(\C=C/2C(=C(C)C(=C/C=3C(=C(C=C)C(=O)N=3)C)/N\2)CCC(O)=O)N1 RCNSAJSGRJSBKK-NSQVQWHSSA-N 0.000 claims 9
- 239000007857 degradation product Substances 0.000 abstract description 7
- RCNSAJSGRJSBKK-DSGIURRASA-N 3-[(2e,5e)-2-[[3-(2-carboxyethyl)-5-[(e)-(3-ethenyl-4-methyl-5-oxopyrrol-2-ylidene)methyl]-4-methyl-1h-pyrrol-2-yl]methylidene]-5-[(4-ethenyl-3-methyl-5-oxopyrrol-2-yl)methylidene]-4-methylpyrrol-3-yl]propanoic acid Chemical compound N1C(=O)C(C)=C(C=C)\C1=C/C1=C(C)C(CCC(O)=O)=C(\C=C\2C(=C(C)C(=C\C=3C(=C(C=C)C(=O)N=3)C)/N/2)CCC(O)=O)N1 RCNSAJSGRJSBKK-DSGIURRASA-N 0.000 description 187
- 241001465754 Metazoa Species 0.000 description 106
- 230000014509 gene expression Effects 0.000 description 64
- 150000001875 compounds Chemical class 0.000 description 57
- 210000004027 cell Anatomy 0.000 description 51
- AQTFKGDWFRRIHR-UHFFFAOYSA-L 3-[18-(2-carboxylatoethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoate;cobalt(2+);hydron Chemical compound [Co+2].[N-]1C(C=C2C(=C(C)C(C=C3C(=C(C)C(=C4)[N-]3)C=C)=N2)C=C)=C(C)C(CCC(O)=O)=C1C=C1C(CCC(O)=O)=C(C)C4=N1 AQTFKGDWFRRIHR-UHFFFAOYSA-L 0.000 description 44
- 239000007789 gas Substances 0.000 description 44
- 239000007788 liquid Substances 0.000 description 44
- 239000000203 mixture Substances 0.000 description 44
- 210000001519 tissue Anatomy 0.000 description 35
- 206010009887 colitis Diseases 0.000 description 34
- 230000006698 induction Effects 0.000 description 32
- 210000002966 serum Anatomy 0.000 description 30
- 230000006378 damage Effects 0.000 description 29
- 108090000623 proteins and genes Proteins 0.000 description 28
- 241000699670 Mus sp. Species 0.000 description 27
- 239000000243 solution Substances 0.000 description 26
- 238000001356 surgical procedure Methods 0.000 description 25
- 241000700159 Rattus Species 0.000 description 23
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 21
- 108010005774 beta-Galactosidase Proteins 0.000 description 21
- 102000005936 beta-Galactosidase Human genes 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 21
- 208000027418 Wounds and injury Diseases 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 20
- 210000002889 endothelial cell Anatomy 0.000 description 19
- 208000014674 injury Diseases 0.000 description 19
- 230000007774 longterm Effects 0.000 description 19
- 210000004988 splenocyte Anatomy 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- 230000000968 intestinal effect Effects 0.000 description 18
- 238000007912 intraperitoneal administration Methods 0.000 description 18
- 230000000747 cardiac effect Effects 0.000 description 17
- 230000001965 increasing effect Effects 0.000 description 17
- 210000003205 muscle Anatomy 0.000 description 17
- 210000001744 T-lymphocyte Anatomy 0.000 description 16
- 108010057270 haemoferritin Proteins 0.000 description 16
- 238000004519 manufacturing process Methods 0.000 description 16
- 108020004999 messenger RNA Proteins 0.000 description 16
- 239000000047 product Substances 0.000 description 15
- 210000000813 small intestine Anatomy 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 14
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 14
- 230000017531 blood circulation Effects 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 239000000463 material Substances 0.000 description 14
- 230000001154 acute effect Effects 0.000 description 13
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 13
- 239000002158 endotoxin Substances 0.000 description 13
- 239000002953 phosphate buffered saline Substances 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 238000012384 transportation and delivery Methods 0.000 description 13
- 102100040247 Tumor necrosis factor Human genes 0.000 description 12
- 229910002092 carbon dioxide Inorganic materials 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 108010085238 Actins Proteins 0.000 description 11
- 206010012735 Diarrhoea Diseases 0.000 description 11
- 102000004889 Interleukin-6 Human genes 0.000 description 11
- 108090001005 Interleukin-6 Proteins 0.000 description 11
- 239000003963 antioxidant agent Substances 0.000 description 11
- 235000006708 antioxidants Nutrition 0.000 description 11
- 230000006907 apoptotic process Effects 0.000 description 11
- 210000001168 carotid artery common Anatomy 0.000 description 11
- 210000000936 intestine Anatomy 0.000 description 11
- 230000035755 proliferation Effects 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 10
- 238000011765 DBA/2 mouse Methods 0.000 description 10
- 102000000588 Interleukin-2 Human genes 0.000 description 10
- 108010002350 Interleukin-2 Proteins 0.000 description 10
- 241001529936 Murinae Species 0.000 description 10
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 10
- 239000012298 atmosphere Substances 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 230000002757 inflammatory effect Effects 0.000 description 10
- 229920006008 lipopolysaccharide Polymers 0.000 description 10
- 230000002035 prolonged effect Effects 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 9
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 9
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 9
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 230000003078 antioxidant effect Effects 0.000 description 9
- NZUPCNDJBJXXRF-UHFFFAOYSA-O bethanechol Chemical compound C[N+](C)(C)CC(C)OC(N)=O NZUPCNDJBJXXRF-UHFFFAOYSA-O 0.000 description 9
- 229960000910 bethanechol Drugs 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 238000011065 in-situ storage Methods 0.000 description 9
- 230000001404 mediated effect Effects 0.000 description 9
- 238000003753 real-time PCR Methods 0.000 description 9
- 230000010410 reperfusion Effects 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 8
- 108010082126 Alanine transaminase Proteins 0.000 description 8
- 108010017500 Biliverdin reductase Proteins 0.000 description 8
- 201000009030 Carcinoma Diseases 0.000 description 8
- 108020004635 Complementary DNA Proteins 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 8
- 102000004558 biliverdin reductase Human genes 0.000 description 8
- 238000010804 cDNA synthesis Methods 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 8
- 229920003045 dextran sodium sulfate Polymers 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000000411 inducer Substances 0.000 description 8
- 230000001681 protective effect Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- FUTVBRXUIKZACV-UHFFFAOYSA-J zinc;3-[18-(2-carboxylatoethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoate Chemical compound [Zn+2].[N-]1C2=C(C)C(CCC([O-])=O)=C1C=C([N-]1)C(CCC([O-])=O)=C(C)C1=CC(C(C)=C1C=C)=NC1=CC(C(C)=C1C=C)=NC1=C2 FUTVBRXUIKZACV-UHFFFAOYSA-J 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 102000003814 Interleukin-10 Human genes 0.000 description 7
- 108090000174 Interleukin-10 Proteins 0.000 description 7
- 238000010171 animal model Methods 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 210000000941 bile Anatomy 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 210000000440 neutrophil Anatomy 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 241000701161 unidentified adenovirus Species 0.000 description 7
- 230000004580 weight loss Effects 0.000 description 7
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 6
- 208000032843 Hemorrhage Diseases 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 206010022653 Intestinal haemorrhages Diseases 0.000 description 6
- 102000003896 Myeloperoxidases Human genes 0.000 description 6
- 108090000235 Myeloperoxidases Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 6
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 230000000740 bleeding effect Effects 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 229910017052 cobalt Inorganic materials 0.000 description 6
- 239000010941 cobalt Substances 0.000 description 6
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 6
- 238000002337 electrophoretic mobility shift assay Methods 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 230000035699 permeability Effects 0.000 description 6
- 238000002203 pretreatment Methods 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000012385 systemic delivery Methods 0.000 description 6
- 102000007469 Actins Human genes 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 5
- 108010057466 NF-kappa B Proteins 0.000 description 5
- 102000003945 NF-kappa B Human genes 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 5
- 210000000683 abdominal cavity Anatomy 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 210000000709 aorta Anatomy 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 210000001072 colon Anatomy 0.000 description 5
- 230000009266 disease activity Effects 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical group C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 208000006454 hepatitis Diseases 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000010412 perfusion Effects 0.000 description 5
- 230000029058 respiratory gaseous exchange Effects 0.000 description 5
- 230000002269 spontaneous effect Effects 0.000 description 5
- 238000007619 statistical method Methods 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- GNLHFBAZSKVVCQ-DKUYZEAMSA-N 3-[(2z,5e)-2-[[3-(2-carboxyethyl)-5-[(z)-(3-ethenyl-4-methyl-5-oxopyrrol-2-ylidene)methyl]-4-methyl-1h-pyrrol-2-yl]methylidene]-5-[(4-ethenyl-3-methyl-5-oxopyrrol-2-yl)methylidene]-4-methylpyrrol-3-yl]propanoic acid;hydron;dichloride Chemical compound Cl.Cl.N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(\C=C/2C(=C(C)C(=C\C=3C(=C(C=C)C(=O)N=3)C)/N\2)CCC(O)=O)N1 GNLHFBAZSKVVCQ-DKUYZEAMSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 230000004568 DNA-binding Effects 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 4
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 4
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 230000001640 apoptogenic effect Effects 0.000 description 4
- 238000003149 assay kit Methods 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000001569 carbon dioxide Substances 0.000 description 4
- 210000001715 carotid artery Anatomy 0.000 description 4
- 230000037020 contractile activity Effects 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 4
- 229960005420 etoposide Drugs 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 210000004907 gland Anatomy 0.000 description 4
- 230000003394 haemopoietic effect Effects 0.000 description 4
- 238000003306 harvesting Methods 0.000 description 4
- 231100000283 hepatitis Toxicity 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 210000001363 mesenteric artery superior Anatomy 0.000 description 4
- 230000008692 neointimal formation Effects 0.000 description 4
- 230000005937 nuclear translocation Effects 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 108010003320 Carboxyhemoglobin Proteins 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 238000011767 DBA/2J (JAX™ mouse strain) Methods 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000018522 Gastrointestinal disease Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101001079623 Homo sapiens Heme oxygenase 1 Proteins 0.000 description 3
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 3
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 3
- 229910002651 NO3 Inorganic materials 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 208000025966 Neurological disease Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 101710119418 Superoxide dismutase [Mn] Proteins 0.000 description 3
- 102100032891 Superoxide dismutase [Mn], mitochondrial Human genes 0.000 description 3
- 101710202572 Superoxide dismutase [Mn], mitochondrial Proteins 0.000 description 3
- 230000006052 T cell proliferation Effects 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 3
- 102000004243 Tubulin Human genes 0.000 description 3
- 108090000704 Tubulin Proteins 0.000 description 3
- 239000012840 University of Wisconsin (UW) solution Substances 0.000 description 3
- 108700042768 University of Wisconsin-lactobionate solution Proteins 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000002424 anti-apoptotic effect Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 238000003287 bathing Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000004004 carotid artery internal Anatomy 0.000 description 3
- 230000001120 cytoprotective effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229940025294 hemin Drugs 0.000 description 3
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 3
- 102000053305 human HMOX1 Human genes 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000004073 interleukin-2 production Effects 0.000 description 3
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 3
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 210000003739 neck Anatomy 0.000 description 3
- 230000001613 neoplastic effect Effects 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 230000007115 recruitment Effects 0.000 description 3
- 230000001850 reproductive effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- NLMDJJTUQPXZFG-UHFFFAOYSA-N 1,4,10,13-tetraoxa-7,16-diazacyclooctadecane Chemical compound C1COCCOCCNCCOCCOCCN1 NLMDJJTUQPXZFG-UHFFFAOYSA-N 0.000 description 2
- 238000009010 Bradford assay Methods 0.000 description 2
- 108010062580 Concanavalin A Proteins 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 206010014824 Endotoxic shock Diseases 0.000 description 2
- 206010014896 Enterocolitis haemorrhagic Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000283074 Equus asinus Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010018374 Glomerulonephritis minimal lesion Diseases 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 206010019837 Hepatocellular injury Diseases 0.000 description 2
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 2
- 206010021263 IgA nephropathy Diseases 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 208000004883 Lipoid Nephrosis Diseases 0.000 description 2
- 208000004852 Lung Injury Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 208000001940 Massive Hepatic Necrosis Diseases 0.000 description 2
- 101000648740 Mus musculus Tumor necrosis factor Proteins 0.000 description 2
- 238000009004 PCR Kit Methods 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000027520 Somatoform disease Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- IOUUIFSIQMVYKP-UHFFFAOYSA-N Tetradecyl acetate Chemical compound CCCCCCCCCCCCCCOC(C)=O IOUUIFSIQMVYKP-UHFFFAOYSA-N 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 206010069363 Traumatic lung injury Diseases 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 238000011316 allogeneic transplantation Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 238000010009 beating Methods 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000133 brain stem Anatomy 0.000 description 2
- 210000000269 carotid artery external Anatomy 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- OEUUFNIKLCFNLN-LLVKDONJSA-N chembl432481 Chemical compound OC(=O)[C@@]1(C)CSC(C=2C(=CC(O)=CC=2)O)=N1 OEUUFNIKLCFNLN-LLVKDONJSA-N 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000008984 colonic lesion Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001378 electrochemiluminescence detection Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000000222 hyperoxic effect Effects 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000001524 infective effect Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
- 210000001630 jejunum Anatomy 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 238000011694 lewis rat Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000001325 log-rank test Methods 0.000 description 2
- 210000005265 lung cell Anatomy 0.000 description 2
- 231100000515 lung injury Toxicity 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 208000027753 pain disease Diseases 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 210000003240 portal vein Anatomy 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 238000000751 protein extraction Methods 0.000 description 2
- 210000001147 pulmonary artery Anatomy 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 238000012755 real-time RT-PCR analysis Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 210000001631 vena cava inferior Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- QGVLYPPODPLXMB-UBTYZVCOSA-N (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9,9a-tetrahydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-5H-cyclopropa[3,4]benzo[1,2-e]azulen-5-one Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(O)C(C)(C)[C@H]3[C@@H]21 QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 206010003162 Arterial injury Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 102100035752 Biliverdin reductase A Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108700031361 Brachyury Proteins 0.000 description 1
- 208000007204 Brain death Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 1
- 101150071146 COX2 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 201000000274 Carcinosarcoma Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 1
- 244000187656 Eucalyptus cornuta Species 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- 206010018372 Glomerulonephritis membranous Diseases 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 238000006595 Griess deamination reaction Methods 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 206010058490 Hyperoxia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 102000008133 Iron-Binding Proteins Human genes 0.000 description 1
- 108010035210 Iron-Binding Proteins Proteins 0.000 description 1
- 239000008002 Krebs-Henseleit bicarbonate buffer Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001676635 Lepidorhombus whiffiagonis Species 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000702623 Minute virus of mice Species 0.000 description 1
- 208000023178 Musculoskeletal disease Diseases 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 108090000913 Nitrate Reductases Proteins 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- RRJHESVQVSRQEX-SUYBPPKGSA-N O-formylcefamandole Chemical compound CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](OC=O)C=3C=CC=CC=3)[C@H]2SC1 RRJHESVQVSRQEX-SUYBPPKGSA-N 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 206010036595 Premature delivery Diseases 0.000 description 1
- 206010036600 Premature labour Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 206010044541 Traumatic shock Diseases 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- QPMSXSBEVQLBIL-CZRHPSIPSA-N ac1mix0p Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1.O([C@H]1[C@]2(OC)C=CC34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O QPMSXSBEVQLBIL-CZRHPSIPSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000000961 alloantigen Effects 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940019748 antifibrinolytic proteinase inhibitors Drugs 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 210000002403 aortic endothelial cell Anatomy 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 208000036815 beta tubulin Diseases 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 239000003633 blood substitute Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 230000000981 bystander Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- JYHHJVKGDCZCCL-UHFFFAOYSA-J carbon monoxide;dichlororuthenium Chemical compound [O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].Cl[Ru]Cl.Cl[Ru]Cl JYHHJVKGDCZCCL-UHFFFAOYSA-J 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 229960002440 cefamandole nafate Drugs 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000008951 colonic inflammation Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 210000004953 colonic tissue Anatomy 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 238000002247 constant time method Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 208000018554 digestive system carcinoma Diseases 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- QFEOTYVTTQCYAZ-UHFFFAOYSA-N dimanganese decacarbonyl Chemical group [Mn].[Mn].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-] QFEOTYVTTQCYAZ-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 210000004921 distal colon Anatomy 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000431 effect on proliferation Effects 0.000 description 1
- 238000000835 electrochemical detection Methods 0.000 description 1
- 238000002848 electrochemical method Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 208000037888 epithelial cell injury Diseases 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000012903 everted gut sac method Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 description 1
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000024557 hepatobiliary disease Diseases 0.000 description 1
- 230000028974 hepatocyte apoptotic process Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 210000003767 ileocecal valve Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003886 intestinal anastomosis Effects 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 238000013147 laser angioplasty Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000016332 liver symptom Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 210000004216 mammary stem cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 210000003622 mature neutrocyte Anatomy 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 1
- 231100000855 membranous nephropathy Toxicity 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
- 229940012189 methyl orange Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000000472 muscarinic agonist Substances 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000006218 nasal suppository Substances 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 229940053050 neomycin sulfate Drugs 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 238000013059 nephrectomy Methods 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 231100001160 nonlethal Toxicity 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 230000001019 normoglycemic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000005164 penile vein Anatomy 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- 230000036972 phasic contraction Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003761 preservation solution Substances 0.000 description 1
- 230000007112 pro inflammatory response Effects 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229940127293 prostanoid Drugs 0.000 description 1
- 150000003814 prostanoids Chemical class 0.000 description 1
- 229950003776 protoporphyrin Drugs 0.000 description 1
- 210000003492 pulmonary vein Anatomy 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 210000005227 renal system Anatomy 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 208000037812 secondary pulmonary hypertension Diseases 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 208000037974 severe injury Diseases 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013595 supernatant sample Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000036977 tonic contraction Effects 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 210000002620 vena cava superior Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/99—Miscellaneous (1.14.99)
- C12Y114/99003—Heme oxygenase (1.14.99.3)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to the treatment of disorders using heme oxygenase-1 and heme degradation products.
- Heme oxygenase-1 catalyzes the first step in the degradation of heme.
- HO-1 cleaves the ⁇ -meso carbon bridge of b-type heme molecules by oxidation to yield equimolar quantities of biliverdin IXa, carbon monoxide (CO), and free iron.
- CO carbon monoxide
- biliverdin is converted to bilirubin via biliverdin reductase, and the release of Fe 2+ from heme induces the expression of the Fe 2+ sequestering protein feiritin. which acts as an anti-oxidant by limiting the ability of Fe 2+ to participate in the generation of free radicals through the Fenton reaction.
- the present invention is based, in part, on the discovery that the administration of degradation products of heme and/or HO-1 can attenuate inflammation and suppress the damage associated with ischemia. Accordingly, the present invention features a method of reducing inflammation in a patient that includes identifying a patient suffering from or at risk
- a treatment including inducing ferritin in the patient; expressing ferritin in the patient; and/or administering a pharmaceutical composition comprising
- HO-1 bilirubin, biliverdin, ferritin, iron, desferoxamine (DFO), salicylaldehyde isonicotinoyl hydrazone (SIH), iron dextran, and/or apoferritin to the patient, in an amount sufficient to reduce inflammation.
- the treatment is administering a pharmaceutical composition that includes biliverdin.
- the pharmaceutical composition can be administered to the patient at a dosage of, for example, about 1 to 1000 micromoles/kg/day, e.g., 10 to 500 ⁇ mols/kg/day, 20 to 200 ⁇ mols/kg/day, or 25 to 100 ⁇ mols/kg/day.
- the treatment can include administering a pharmaceutical composition that includes bilirubin to the patient.
- the pharmaceutical composition can be administered to a patient to generate serum levels of bilirubin in a range of from about 1 to about 300 ⁇ mols/L, e.g., about 10 to about 200 ⁇ mols/L, or about 50 to about 100 ⁇ mols/L.
- Individual doses of bilirubin can be administered, which can fall within the range of about 1 to 1000 mg/kg, e.g., 10 to 500 mg/kg, 20 to 200 mg/kg, or 25 to 150 mg/kg.
- the treatment can include administering a pharmaceutical composition that includes apoferritin to the patient.
- the pharmaceutical composition can be administered to the patient at a dosage of, for example, about 1 to 1000 mg/kg, e.g., 10 to 500 mg/kg, 20 to 200 mg/kg, or 25 to 150 mg/kg.
- the treatment can also include administering a pharmaceutical composition that includes DFO to the patient.
- the pharmaceutical composition can be administered to the patient at a dosage of, for example, about 0.1 to 1000 mg/kg, e.g., 0.5 to 800 mg/kg, 1 to 600 mg/kg, 2 to 400 mg/kg, or 2.5 to 250 mg/kg.
- the treatment can include administering a pharmaceutical composition that includes iron dextran to the patient.
- the pharmaceutical composition can be administered to the patient at a dosage of, for example, about 1 to 1000 mg/kg, e.g., 10 to 900 mg/kg, 100 to 800 mg/kg, 300 to 700 mg/kg, or 400 to 600 mg/kg.
- free iron e.g., in the form of iron supplements, can be delivered to the patient.
- the treatment can also include administering a pharmaceutical composition that includes salicylaldehyde isonicotinoyl hydrazone (SIH) to the patient.
- SIH salicylaldehyde isonicotinoyl hydrazone
- the pharmaceutical composition can be administered to the patient orally or parenterally at a dosage of, for example, about 0.02 to 100 mmol/kg, e.g., about 0.02 to 10 mmol/kg, e.g., 0.02 to 50 mmol/kg, or 0.2 to 20 mmol/kg.
- the inflammation can be associated with a condition including, but not limited to, asthma, adult respiratory distress syndrome, interstitial pulmonary fibrosis, pulmonary emboli, chronic obstructive pulmonary disease, primary pulmonary hypertension, chronic pulmonary emphysema, congestive heart failure, peripheral vascular disease, stroke, atherosclerosis, ischemia-reperfusion injury, heart attacks, glomerulonephritis, conditions involving inflammation of the kidney, infection of the genitourinary tract, viral and toxic hepatitis, cirrhosis, ileus, necrotizing enterocolitis, specific and non-specific inflammatory bowel disease, rheumatoid arthritis, deficient wound healing, Alzheimer's disease, Parkinson's disease, graft versus host disease, or hemorrhagic, septic, or anaphylactic shock.
- a condition including, but not limited to, asthma, adult respiratory distress syndrome, interstitial pulmonary fibrosis, pulmonary emboli, chronic obstructive
- the inflammation is inflammation of the heart, lung, liver, pancreas, joints, eye, bronchi, spleen, brain, skin, and/or kidney.
- the inflammation can also be an inflammatory condition localized in the gastrointestinal tract.
- the inflammatory condition can be, for example, amoebic dysentery, bacillary dysentery, schistosomiasis, campylobacter enterocolitis, yersinia enterocolitis, enterobius vermicularis, radiation enterocolitis, ischaemic colitis, eosinophilic gastroenteritis, ulcerative colitis, indeterminate colitis, and Crohn's disease.
- the method can further include the step(s) of inducing and/or expressing HO- 1 in the patient and/or administering a pharmaceutical composition comprising carbon monoxide to the patient.
- the invention features a method of transplanting an organ, which includes administering to a donor a treatment including inducing HO-1 or ferritin in the donor; expressing ferritin in the donor; and/or administering a pharmaceutical composition comprising HO-1, bilirubin, biliverdin, ferritin, desferoxamine, salicylaldehyde isonicotinoyl hydrazone, iron dextran, and/or apoferritin to the donor; obtaining an organ from the donor; and transplanting the organ into a recipient, wherein the treatment administered is sufficient to enhance survival or function of the organ after transplantation into the recipient.
- the method further includes the step(s) of inducing and/or expressing HO-1 in the donor and/or administering a pharmaceutical composition comprising carbon monoxide to the donor.
- the invention also features a method of transplanting an organ, which includes providing an organ of a donor; administering to the organ ex vivo a treatment including inducing HO-1 or ferritin in the organ, expressing HO-1 or ferritin in the organ, and/or administering a pharmaceutical composition comprising HO-1, bilirubin, biliverdin, ferritin, desferoxamine, salicylaldehyde isonicotinoyl hydrazone, iron dextran, and/or apoferritin; and transplanting the organ into a recipient, wherein treatment administered to the organ is sufficient to enhance survival or function of the organ after transplantation.
- the method further includes the step(s) of inducing and/or expressing HO-1 in the organ and/or administering a pharmaceutical composition comprising carbon monoxide to the organ.
- the invention features a method of transplanting an organ, which includes providing an organ from a donor; transplanting the organ into a recipient; and before, during, or after the transplanting step, administering to the recipient a treatment including inducing HO-1 or ferritin in the recipient, expressing HO-1 or ferritin in the recipient, and/or administering a pharmaceutical composition comprising HO-1, bilirubin, biliverdin, ferritin, desferoxamine, salicylaldehyde isonicotinoyl hydrazone, iron dextran, and/or apoferritin to the recipient, wherein the treatment administered to the recipient is sufficient to enhance survival or function of the organ after transplantation of the organ to the recipient.
- the method further includes the step(s) of inducing and/or expressing
- the invention provides a method of performing angioplasty on a patient, which includes performing angioplasty on the patient; and before, during, or after the performing step, administering a treatment including inducing HO-1 or ferritin in the patient, expressing HO-1 or ferritin in the patient, and/or administering a pharmaceutical composition comprising HO-1, bilirubin, biliverdin, ferritin, desferoxamine, salicylaldehyde isonicotinoyl hydrazone, iron dextran, and/or apoferritin to the patient.
- the method further includes the step(s) of inducing and/or expressing HO-1 in the patient and/or administering a pharmaceutical composition comprising carbon monoxide to the patient.
- the invention also features a method of performing vascular surgery on a patient, which includes performing vascular surgery on the patient; and before, during, or after performing the vascular surgery, administering to the patient at least one treatment including inducing HO-1 or ferritin in the patient, expressing ferritin in the patient, and/or administering a pharmaceutical composition comprising HO-1, bilirubin, biliverdin, ferritin, desferoxamine, salicylaldehyde isonicotinoyl hydrazone, iron dextran, and/or apoferritin.
- the method includes the step(s) of inducing and/or expressing HO-1 in the patient and/or administering a pharmaceutical composition comprising carbon monoxide to the patient.
- the invention features a method of treating a cellular proliferative and/or differentiative disorder in a patient, which includes identifying a patient suffering from or at risk for a cellular proliferative and/or differentiative disorder; and administering to the patient at least one treatment including inducing ferritin in the patient, expressing ferritin in the patient, and/or administering a pharmaceutical composition comprising HO-1, bilirubin, biliverdin, ferritin, iron, desferoxamine, salicylaldehyde isonicotinoyl hydrazone, iron dextran, and/or apoferritin to the patient, in an amount sufficient to treat the cellular proliferative and/or differentiative disorder, hi certain embodiments, the method further includes the step(s) of inducing and/or expressing HO-1 in the patient and/or administering a pharmaceutical composition comprising carbon monoxide to the patient.
- the invention features a method of reducing the effects of ischemia in a patient, which includes identifying a patient suffering from or at risk for ischemia; and administering to the patient at least one treatment including inducing ferritin in the patient, expressing ferritin in the patient, and or administering a pharmaceutical composition comprising HO-1, bilirubin, biliverdin, ferritin, iron, desferoxamine, salicylaldehyde isonicotinoyl hydrazone, iron dextran, and/or apoferritin to the patient, in an amount sufficient to reduce the effects of ischemia.
- the method further includes the step(s) of inducing and/or expressing HO-1 in the patient and/or administering a pharmaceutical composition comprising carbon monoxide to the patient.
- composition is used throughout the specification to describe a gaseous, liquid, or solid composition containing an active ingredient, e.g., HO-1 or ferritin (or an inducer of HO-1 or ferritin), bilirubin, and/or biliverdin, that can be administered to a patient and/or an organ.
- an active ingredient e.g., HO-1 or ferritin (or an inducer of HO-1 or ferritin), bilirubin, and/or biliverdin
- the invention contemplates use of any two, three, four, or five of these in combination or in sequence.
- the skilled practitioner will recognize which form of the pharmaceutical composition, e.g., gaseous, liquid, and/or solid, is preferred for a given application. Further, the skilled practitioner will recognize which active ingredient(s) should be included in the pharmaceutical composition for a given application.
- patient is used throughout the specification to describe an animal, human or non-human, to whom treatment according to the methods of the present invention is provided.
- Veterinary applications are clearly anticipated by the present invention.
- the term includes but is not limited to mammals, e.g., humans, other primates, pigs, rodents such as mice and rats, rabbits, guinea pigs, hamsters, cows, horses, cats, dogs, sheep and goats.
- ⁇ ективное amount refers to the administration of a pharmaceutical compositions(s) described herein in an amount or concentration and for period of time including acute or chronic administration and periodic or continuous administration that is effective within the context of its administration for causing an intended effect or physiological outcome.
- treat or “treatment,” are used herein to describe delaying the onset of, inhibiting, or alleviating the effects of a disease or condition, e.g., a disease or condition described herein.
- HO-1 and/or any of the degradation products of heme, e.g., bilirubin, biliverdin, ferritin, iron, desferoxamine (DFO), salicylaldehyde isonicotinoyl hydrazone (SIH), iron dextran, and/or apoferritin, in the manufacture of a medicament for the treatment or prevention of inflammation or the damage associated with ischemia, e.g., transplantation-related ischemia.
- the medicament can be used in a method for treating or preventing inflammation in a patient suffering from or at risk for inflammation.
- the medicament can also be used in a method of organ transplantation, e.g., to reduce inflammation and ischemia- reperfusion injury.
- the medicament can also be used in a method of performing vascular surgery or angioplasty on a patient.
- the medicament can also be used in a method of treating a cellular proliferative and/or differentiative disorder in a patient.
- the medicament can also be used in a method of treating or preventing the effects of ischemia in a patient.
- the medicament can be in any form described herein, and can be administered alone or in combination with, e.g., CO.
- FIG. 1A is a photograph of a gel showing the results of semi-quantitative PCR analysis of HO-1 and ⁇ -actin mRNA levels after induction of DSS-colitis in control animals.
- FIG. IB is a bar graph illustrating the changing ratio of HO-1 : ⁇ -actin mRNA levels after induction of DSS-colitis in control animals.
- X-axis days.
- FIG. 1C is a photograph of a Western blot showing an increase in HO-1 protein levels after induction of DSS-colitis in control animals, ⁇ -tubulin was used as a internal reference.
- FIG. 2A is a photograph of a gel showing the results of semi-quantitative PCR analysis of HO-1 and ⁇ -actin mRNA levels after induction of DSS-colitis in animals treated with cobalt protoporphyrin (CoPP).
- CoPP cobalt protoporphyrin
- FIG. 2B is a bar graph illustrating the changing ratio of HO-1: ⁇ -actin mRNA levels after induction of DSS-colitis in animals treated with CoPP.
- FIG. 2C is a photograph of a Western blot showing an increase in HO-1 protein levels after induction of DSS-colitis in animals treated with CoPP. ⁇ -tubulin was used as a loading control.
- FIG. 3 A is a bar graph that illustrates the effect of cobalt protoporphyrin treatment on weight loss associated with DSS-colitis, as observed on day 7 of the experiment.
- FIG. 3B is a bar graph that illustrates the effect of cobalt protoporphyrin treatment on the
- FIG. 3C is a line graph that illustrates the effect of cobalt protopo hyrin treatment on the DSS-colitis DAI over a period of 7 days.
- FIG. 3D is a line graph that illustrates the effect of cobalt treatment on intestinal bleeding associated with DSS-colitis over a period of 7 days.
- FIG. 3E is a line graph that illustrates the effect of cobalt protopo ⁇ hyrin induction of
- FIG. 4A is a set of four photomicrographs of cryptal structures at lOx (top row) and 40x (bottom row) magnification in untreated control animals (NT, left column) and CoPP-treated animals (COPP, right column).
- FIG. 4B is a bar graph illustrating the relatively decreased damage to mucosal glands in animals treated with CoPP as compared to untreated controls, as measured by crypt scores.
- FIG. 5 A is a bar graph that illustrates the effect of treatment with biliverdin, DFO or carbon monoxide on weight loss associated with DSS-colitis, as observed on day 7 of the experiment.
- NT no treatment
- CO carbon monoxide
- DFO desferoxamine.
- FIG. 5B is a bar graph that illustrates the effect of treatment with biliverdin,
- FIG. 5C is a line graph that illustrates the effect of treatment with biliverdin on the DSS-colitis DAI over a period of 7 days.
- FIG. 5D is a line graph that illustrates the effect of treatment with biliverdin on intestinal bleeding associated with DSS-colitis over a period of 7 days.
- FIG. 5E is a line graph that illustrates the effect of treatment with biliverdin on stool abnormalities associated with DSS-colitis over a period of 7 days.
- FIG. 6 A is a set of four photomicrographs of cryptal structures at lOx (top row) and 40x (bottom row) magnification in untreated control animals (NT, left column) and biliverdin-treated animals (right column).
- FIG. 6B is a bar graph illustrating the relatively decreased damage to mucosal glands in animals treated with biliverdin as compared to untreated controls, as measured by crypt scores.
- FIG. 7A is a set of photographs showing the results of Western blot analysis of HO-1 (top row) and ⁇ -actin (bottom row) protein expression in spleen (left column) and heart (right column) at 0, 1, 2, 4, and 7 days after CoPPIX administration.
- FIG. 7B is a bar graph illustrating the increase in HO-1 expression levels at 0, 1, 2, 4, and 7 days after CoPPIX administration.
- FIG. 7C is a bar graph illustrating the effect of treatment with CoPPIX or ZnPPIX on bilirubin levels.
- FIG. 7D is a line graph illustrating the percent survival of cardiac allografts in animals treated with CoPPIX or ZnPPIX.
- FIG. 8 A is a line graph illustrating the % survival of cardiac allografts in animals treated with biliverdin on three different dosage schedules.
- FIG. 8B is a line graph illustrating the increase in serum bilirubin levels with time after administration of biliverdin.
- FIG. 8C is a line graph illustrating percent survival in mice challenged by second set transplantation using cardiac allografts from donor (DBA/2J) or third party (FVB) mouse strain.
- FIG. 9 is a bar graph illustrating the effect on proliferation of splenocytes in animals treated with CoPPIX, ZnPPIX, or biliverdin (lx/day or 3x/day).
- FIG. 10A is a bar graph illustrating the effect of different doses of biliverdin on proliferation of splenocytes stimulated with ConA.
- FIG. 1 OB is a bar graph illustrating the effect of different doses of biliverdin on proliferation of splenocytes stimulated with anti-CD3 mAb.
- FIG. IOC is a bar graph illustrating the effect of different doses of biliverdin on proliferation of splenocytes stimulated with irradiated DBA/2 splenocytes.
- FIG. 10D is a bar graph illustrating the effect of different doses of biliverdin on proliferation of splenocytes co-stimulated with anti-CD3 mAb plus anti-CD28.
- FIG. 11A is a bar graph illustrating the suppressive effect of different doses of biliverdin on IL-2 secretion by splenocytes.
- FIG. 1 IB is a bar graph illustrating the effect of adding exogenous IL-2 on the suppressive effect of different doses of biliverdin on IL-2 secretion by splenocytes.
- FIG. 11C is a panel of three graphs showing the results of FACS analysis of CD25 expression in splenocytes stimulated with anti-CD3 mAb or anti-CD3 mAb plus biliverdin.
- FIG. 1 ID is a pair of photographs illustrating the effect of biliverdin on nuclear translocation of NF- ⁇ B or NFAT, as measured by DNA-binding.
- FIG. 12A is a line graph illustrating percent graft survival in animals treated with CoPP or ZnPP alone (donor treated on day -2 (D-2) and day -1 (D-1), recipient treated from day -1 (D-1) to day +13 (D13)), DSI alone (recipient treated at day 0 (DO)), or CoPP or ZnPP (donor treated on D-2 and D-1, recipient treated from D-1 to D13) plus DSI (recipient treated at DO).
- FIG. 12B is a line graph illustrating percent graft survival in animals treated with CoPP or ZnPP alone (donor treated on day -2 (D-2) and day -1 (D-1), recipient treated from day -8 (D-8) to day +6 (D6)), DST alone (recipient treated at D-7), or CoPP or ZnPP (donor treated for D-2 and D-1, recipient treated from D-8 to D6) plus DSI (recipient treated at day -7 (D-7)).
- FIG. 13 A is a pair of bar graphs illustrating percent cell survival in BAEC (left panel) or murine 2F-2B EC (ATCC; right panel) cotransfected with ⁇ -galactosidase plus control (pcDNA3 or pcDNA3/HO-l) or pcDNA3/H-Ferritin. Black bars indicate EC treated with TNF- ⁇ and Act.D. Gray bars represent EC treated with Act.D. One representative experiment out of six is shown. All results shown are the mean ⁇ SD from duplicate wells.
- FIG. 13B is a pair of bar graphs illustrating percent cell survival in murine 2F- 2B cells cotransfected with ⁇ -galactosidase plus control (pcDNA3) or pcDNA3/H- ferritin. Gray bars represent untreated EC and black bars represent EC treated with etoposide (200 ⁇ M, 8h; left panel) or subjected to serum deprivation (0.1% FCS, 24 hours; right panel). One representative experiment out of three is shown. All results shown are the mean ⁇ SD from duplicate wells.
- FIG. 13C is a bar graph illustrating percent cell survival in murine 2F-2B cells cotransfected with ⁇ -galactosidase plus increasing amounts of pcDNA/H-ferritin as indicated. Cells transfected with pcDNA3 or pcDNA3/HO-l were used as controls. Black bars indicate EC treated with TNF- ⁇ and Act.D. Gray bars represent EC treated with Act.D. One representative experiment out of three is shown. All results shown are the mean ⁇ SD from duplicate wells.
- FIG. 14A is a bar graph illustrating bile production in livers harvested from
- FIG. 14B is a bar graph illustrating recipient survival in a Kaplan Mayer format. Livers transduced with control ⁇ -galactosidase or H-ferritin adenoviruses were transplanted into syngeneic recipients. Eight to ten animals were analyzed per group. Prolonged survival in recipients receiving H-ferritin recombinant adeno virus transduced livers was significantly enhanced as compared to recipients transplanted with non-transduced or ⁇ -galactosidase recombinant adenovirus transduced livers (p ⁇ .001).
- FIG. 14C is a set of photomicrographs of apoptosis in non-transduced livers or livers transduced with control ⁇ -galactosidase or H-ferritin adenoviruses transplanted into syngeneic recipients. Apoptosis was detected 24 hours after transplantation as described herein. Apoptotic cells are signaled with black arrows. Magnifications are 100 x (a, c, e) or 400 x (b, d, f).
- FIG. 15 is a schematic illustration of a model for the cytoprotective action of ferritin.
- Top panel control; bottom panel: in cells transduced with recombinant H- ferritin adenovirus.
- SOD superoxide dismutase.
- FIG. 16 is a line graph illustrating the effect on islet transplant survival of treatment of the donor, recipient, or both with CoPP.
- FIG. 17 is a line graph illustrating the effect on islet transplant survival of treatment of the donor and recipient with bilirubin or biliverdin.
- FIG. 18 is a pair of photomicrographs illustrating the effect of pre-treatment with biliverdin on neointimal formation in rat carotid arteries after balloon injury.
- FIG. 20 is a bar graph illustrating the effect of biliverdin pre-treatment on neutrophil accumulation in the lungs of rats treated with LPS.
- 200 of 200 cells are macrophages, no neutrophils are present.
- FIG. 21 is a bar graph illustrating the effect of biliverdin pre-treatment on protein accumulation in the lungs of rats treated with LPS. Normal baseline levels are around 30.
- FIG. 22 is a bar graph illustrating the effect of biliverdin pre-treatment on IL- 10 levels in rats treated with LPS.
- FIGS. 23A-23D are bar graphs illustrating the effect of treatment with biliverdin on levels of IL-6, IL-10, TNF ⁇ and IL-l ⁇ , respectively, in a small intestine transplantation model.
- Real time RT-PCR analysis revealed a significant increase in mRNA expression of IL-6, IL-10, TNF- ⁇ and IL-lb in graft muscularis 4 hours after transplantation compared to unoperated animals.
- the mean expressions for IL-6 and IL-lb mRNA, but not IL-10 or TNF- ⁇ were significantly reduced.
- NM Normal
- BV biliverdin
- SITx small intestine transplant
- FIGS. 24A-24D are bar graphs illustrating the effect of treatment with biliverdin on levels of COX-2; iNOS; ICAM-1, and MnSOD, respectively, in a small intestine transplantation model.
- iNOS and COX-2 gene expression was significantly upregulated in the muscularis of the transplanted intestine.
- BV treatment significantly reduced the expression of iNOS, COX-2, ICAM- 1 and MnSOD mRNA in the graft muscularis extracts.
- FIG. 25 is a line graph illustrating the effect of treatment with increasing doses of bethanechol on contractility response in transplanted small intestine. Jejunal circular muscle strips from control animals (filled triangles) and unoperated animals receiving BV treatment (filled squares) showed a dose-dependent increase in contractile area in response to bethanechol. This activity was significantly diminished in graft muscle taken 24 hours following transplantation (open triangles). Significant improvement was measured in transplanted animals treated with BV (open squares)
- FIGS. 26A-26B are bar graphs illustrating the effect of treatment with biliverdin on permeability and blood flow, respectively, in a small intestine transplant model.
- FIG. 27 is a line graph illustrating the effect of treatment with biliverdin on antioxidant capacity in a small intestine transplant model.
- the present invention includes providing, e.g., administering, inducing and/or expressing any or all of the products of heme degradation in a patient to treat various diseases or conditions, e.g., inflammation, and/or to improve the outcome of various surgical procedures, e.g., transplant surgery.
- heme oxygenase-1 can be provided to a patient in conjunction with administration of any or all of the products of heme degradation, e.g., carbon monoxide (CO), biliverdin, bilirubin, iron, and ferritin.
- CO carbon monoxide
- biliverdin biliverdin
- bilirubin iron
- ferritin ferritin
- HO-1 can be provided to a patient by inducing or expressing HO-1 in the patient, or by administering exogenous HO-1 directly to the patient.
- induce(d) means to cause increased production of a protein, e.g., HO-1 or ferritin, in the body of a patient, using the patient's own endogenous (e.g., non- recombinant) gene that encodes the protein.
- HO-1 can be induced in a patient by any method known in the art. For example, production of HO-1 can be induced by hemin, by iron protoporphyrin, or by cobalt protoporphyrin.
- non-heme agents including heavy metals, cytokines, hormones, nitric oxide, COCl 2 , endotoxin and heat shock are also strong inducers of HO-1 expression (Otterbein et ah, Am. J. Physiol. Lung Cell Mol. Physiol. 279:L1029-L1037, 2000; Choi et al, Am. J. Respir. Cell Mol. Biol. 15:9-19, 1996; Maines, Annu. Rev. Pharmacol. Toxicol. 37:517-554, 1997; and Tenhunen et al, J. Lab. Clin. Med. 75:410-421, 1970).
- HO-1 is also highly induced by a variety of agents and conditions that create oxidative stress, including hydrogen peroxide, glutathione depletors, UV irradiation and hyperoxia (Choi et al, Am. J. Respir. Cell Mol. Biol. 15: 9-19, 1996; Maines, Annu. Rev. Pharmacol. Toxicol. 37:517-554, 1997; and Keyse et al, Proc. Natl. Acad. Sci. USA 86:99-103, 1989).
- a "pharmaceutical composition comprising an inducer of HO-1” means a pharmaceutical composition containing any agent capable of inducing HO-1 in a patient, e.g., any of the agents described herein, e.g., hemin, iron protopo ⁇ hyrin, and/or cobalt protoporphyrin.
- HO-1 can be expressed in a patient via gene transfer.
- expression(ed) means to cause increased production of a protein, e.g., HO-1 or ferritin, in the body of a patient using an exogenously administered gene (e.g., a recombinant gene).
- the HO-1 or ferritin is preferably of the same species (e.g., human, mouse, rat, etc.) as the patient, in order to minimize any immune reaction.
- Expression could be driven by a constitutive promoter (e.g., cytomegalovirus promoters) or a tissue-specific promoter (e.g., milk whey promoter for mammary cells or albumin promoter for liver cells).
- a constitutive promoter e.g., cytomegalovirus promoters
- tissue-specific promoter e.g., milk whey promoter for mammary cells or albumin promoter for liver cells.
- An appropriate gene therapy vector e.g., retroviruses, adenoviruses, adeno-associated viruses (AAV), pox (e.g., vaccinia) viruses, human immunodeficiency virus (HIV), the minute virus of mice, hepatitis B virus, influenza virus, He ⁇ es Simplex Virus- 1, and lentiviruses
- retroviruses e.g., retroviruses, adenoviruses, adeno-associated viruses (AAV), pox (e
- HO-1 or ferritin would be administered to the patient orally, by inhalation, or by injection at a location appropriate for treatment of a condition described herein. Particularly preferred is local administration directly to the site of the condition.
- plasmid vectors encoding HO-1 or ferritin can be administered, e.g., as naked DNA, in liposomes, or in microparticles.
- exogenous HO-1 protein can be directly administered to a patient by any method known in the art.
- Exogenous HO-1 can be directly administered in addition to, or as an alternative to the induction or expression of HO-1 in the patient as described herein.
- the HO-1 protein can be delivered to a patient, for example, in liposomes, and/or as a fusion protein, e.g., as a TAT-fusion protein (see, e.g., Becker- Hapak et al., Methods 24, 247-256, 2001).
- HO-1 can be induced and/or expressed in, and/or administered to donors, recipients, and/or the organ to be transplanted.
- Heme Degradation Products see, e.g., Becker- Hapak et al., Methods 24, 247-256, 2001.
- Heme degradation products include carbon monoxide, iron, biliverdin, bilirubin and (apo)ferritin. Any of the above can be provided to patients, e.g., as an active ingredient in a pharmaceutical composition or by other methods as described herein. Biliverdin and Bilirubin
- biliverdin and “bilirubin” refer to the linear tetrapyrrole compounds that are produced as a result of heme degradation.
- compositions comprising biliverdin and/or bilirubin are typically administered to patients in aqueous or solid fonns.
- Biliverdin and bilirubin useful in the methods of the invention can be obtained from any commercial source, e.g., any source that supplies biochemicals for medical or laboratory use. In the preparation, use, or storage of biliverdin and bilirubin, it is recommended that the compounds be exposed to as little light as possible.
- biliverdin and/or bilirubin amount of biliverdin and/or bilirubin to be included in pharmaceutical compositions and to be administered to patients will depend on abso ⁇ tion, distribution, inactivation, and excretion rates of the bilirubin and/or biliverdin, as well as other factors known to those of skill in the art. Effective amounts of biliverdin and/or bilirubin are amounts that are effective for treating a particular disease or condition.
- Effective amounts of biliverdin can fall within the range of about 1 to 1000 micromoles/kg/day, e.g., at least 10 ⁇ mols/kg/day, e.g., at least 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, or 900 micromoles/kg/day.
- Preferred ranges include 10 to 500 ⁇ mols/kg/day, 20 to 200 ⁇ mols/kg/day, and 25 to 100 ⁇ mols/kg/day.
- the present invention contemplates that doses of biliverdin above 1000 micromoles/kg/day can be administered to patients.
- the entire dose of biliverdin can be administered as a single dose, in multiple doses, e.g., several doses per day, or by constant infusion.
- Effective amounts of bilirubin can be administered to a patient to generate serum levels of bilirubin in a range of from about 1 to about 300 ⁇ mols/L, e.g., at least about 10 to about 200 ⁇ mols/L, or about 50 to about 100 ⁇ mols/L.
- individual doses of bilirubin can be administered, which can fall within the range of about 1 to 1000 mg/kg, e.g., at least 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, or 900 mg/kg.
- Preferred ranges include 10 to 500 mg/kg, 20 to 200 mg/kg, and 25 to 150 mg/kg.
- the entire dose of bilirubin can be administered as a single dose, in multiple doses, e.g., several doses per day, or by constant infusion.
- compositions comprising biliverdin and/or bilirubin are contemplated by the present invention, depending upon, e.g., the severity or persistence of the disease or condition in the patient.
- the compositions can be delivered to the patient for a time (including indefinitely) sufficient to treat the condition and exert the intended pharmacological or biological effect.
- biliverdin and/or bilirubin can be bound to carriers.
- Such carriers include, for example, albumin or cyclodextrin. Binding of biliverdin and/or bilirubin to such a carriers could increase the solubility of biliverdin and/or bilirubin, thereby preventing deposition of biliverdin and/or bilirubin in the tissues.
- the present invention contemplates that it is possible to individually administer unbound biliverdin and/or bilirubin and albumin to the patient to produce the desired effect.
- biliverdin reductase can be induced, expressed, and/or administered to a patient in situations where it is deemed desirable to increase bilirubin levels in the patient.
- the biliverdin reductase protein can be delivered to a patient, for example, in liposomes.
- the present invention contemplates that increased levels of biliverdin reductase can be generated in a patient via gene transfer.
- An appropriate gene therapy vector e.g., plasmid, adenovirus, adeno-associated virus (AAV), lentivirus, or any of the other gene therapy vectors mentioned herein
- plasmid e.g., plasmid, adenovirus, adeno-associated virus (AAV), lentivirus, or any of the other gene therapy vectors mentioned herein
- AAV adeno-associated virus
- lentivirus lentivirus
- a vector that encodes biliverdin reductase is administered to an organ affected by a condition described herein and biliverdin is subsequently or simultaneously administered to the organ, such that the biliverdin reductase breaks down the biliverdin to produce bilirubin in the organ.
- the release of free iron by the action of HO-1 on heme stimulates the induction of apoferritin, which rapidly sequesters the iron to form ferritin.
- the present invention includes inducing or expressing ferritin in a patient to treat inflammation or ischemia or cell proliferation associated with various diseases or conditions in the patient.
- Ferritin can be induced in a patient by any method known in the art. For example, ferritin can be induced by administering iron dextran to the patient. As another example, ferritin levels in a patient can be increased by exposing the patient to ultraviolet radiation (Otterbein et al., Am. J. Physiol. Lung Cell Mol. Physiol. 279:L1029-L1037, 2000).
- a "pharmaceutical composition comprising an inducer of ferritin” means a pharmaceutical composition containing any agent capable of inducing ferritin, e.g., heme, iron, and/or iron dextran, in a patient.
- a pharmaceutical composition comprising an inducer of ferritin is administered to a patient in aqueous or solid form.
- Inducers of ferritin, e.g., iron or iron dextran, useful in the methods of the invention can be obtained from any commercial source, e.g., a commercial source that supplies chemicals for medical or laboratory use.
- an effective amount of an inducer of ferritin is an amount that is effective for treating a disease or condition.
- Effective doses of iron dextran can be administered once or several times per day, and each dose can fall within the range of about 1 to 1000 mg/kg, e.g., at least 2, 2.5, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 250, 300, 400, 500, 600, 700, 800, or 900 mg/kg.
- Preferred ranges for iron dextran include 10 to 900 mg/kg, 100 to 800 mg/kg, 300 to 700 mg/kg, or 400 to 600 mg/kg.
- Free iron can be delivered to the patient, for example, as one or multiple doses of a commercially available iron supplement, e.g., a tablet containing iron.
- ferritin e.g., H-chain ferritin
- An appropriate gene therapy vector (as described herein) would be administered to the patient orally or by injection or implantation at a location appropriate for treatment of a condition described herein.
- exogenous ferritin can be directly administered to a patient by any method known in the art. Exogenous ferritin can be directly administered in addition to, or as an alternative to the induction or expression of ferritin in the patient as described herein.
- the ferritin protein can be delivered to a patient, for example, in liposomes, and/or as a fusion protein, e.g., as a TAT-fusion protein (see, e.g., Becker- Hapak et al, Methods 24:247-256, 2001).
- iron-binding molecules can be administered to the patient to create or enhance the desired effect, e.g., to reduce free iron levels.
- the present invention contemplates that apoferritin can be administered to a patient, as well as any type of iron chelator, e.g., desferoxamine (DFO) or salicylaldehyde isonicotinoyl hydrazone (SIH) (see, e.g., Blaha et al, Blood 91(ll):4368-4372, 1998) to create or enhance the desired effect.
- DFO desferoxamine
- SIH salicylaldehyde isonicotinoyl hydrazone
- Effective doses of DFO can be admimstered once or several times per day, and each dose can fall within the range of from about 0.1 to 1000 mg/kg, e.g., at least 2, 2.5., 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 250, 300, 400, 500, 600, 700, 800, 5 or 900 mg/kg.
- Preferred ranges for DFO include 0.5 to 800 mg/kg, 1 to 600 mg/kg, 2 to 400 mg/kg, or 2.5 to 250 mg/kg.
- Effective doses of SIH can be administered once or several times per day, and each dose can fall within the range of from about 0.02 to 100 mmol/kg, e.g., 0.02 to 50 mmol/kg, or 0.2 to 20 mmol/kg.
- o Effective doses of apoferritin can be administered once or several times per day, and each dose can fall within the range of about 1 to 1000 mg/kg, e.g., at least 2, 2.5, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 250, 300, 400, 500, 600, 700, 800, or 900 mg/kg.
- Preferred ranges include 10 to 500 mg/kg, 20 to 200 mg/kg, and 25 to 150 mg/kg.
- any of the above e.g., iron chelators, e.g., DFO or SIH, iron dextran, and apoferritin
- Carbon Monoxide e.g., carbon Monoxide
- carbon monoxide (or “CO) as used herein describes molecular carbon monoxide in its gaseous state, compressed into liquid form, or dissolved in 5 aqueous solution.
- An effective amount of carbon monoxide for use in the present invention is an amount that is effective for treating a disease or condition.
- effective amounts of carbon monoxide generally fall within the range of about 0.0000001% to about 0.3% by weight, e.g., 0.0001% to about 0.25% by weight, preferably at least about 0.001%, e.g., 0.005%, 0.010%, 0.02%, 0.025%, 0.03%, 0 0.04%, 0.05%, 0.06%, 0.08%, 0.10%, 0.15%, 0.20%, 0.22%, or 0.24% by weight of carbon monoxide.
- a carbon monoxide composition can be a gaseous carbon monoxide composition.
- Compressed or pressurized gas useful in the methods of the invention can be obtained from any commercial source, and in any type of vessel appropriate for storing compressed gas.
- compressed or pressurized gases can be obtained from any source that supplies compressed gases, such as oxygen, for medical use.
- the pressurized gas including carbon monoxide used in the methods of the present invention can be provided such that all gases of the desired final composition (e.g., CO, He, NO, CO 2 , O , N 2 ) are in the same vessel.
- the methods of the present invention can be performed using multiple vessels containing individual gases.
- a single vessel can be provided that contains carbon monoxide, with or without other gases, the contents of which can be optionally mixed with the contents of other vessels, e.g., vessels containing oxygen, nitrogen, carbon dioxide, compressed air, or any other suitable gas or mixtures thereof.
- Gaseous carbon monoxide compositions administered to a patient according to the present invention typically contain 0% to about 79% by weight nitrogen, about 21 % to about 100% by weight oxygen and about 0.0000001 % to about 0.3% by weight (corresponding to about 1 ppb or 0.001 ppm to about 3,000 ppm) carbon monoxide.
- the amount of nitrogen in the gaseous composition is about 79% by weight
- the amount of oxygen is about 21% by weight
- the amount of carbon monoxide is about 0.0001% to about 0.25% by weight, preferably at least about 0.001%, e.g., 0.005%, 0.010%, 0.02%, 0.025%, 0.03%, 0.04%, 0.05%, 0.06%, 0.08%, 0.10%, 0.15%, 0.20%, 0.22%, or 0.24% by weight of carbon monoxide.
- gaseous carbon monoxide compositions having concentrations of carbon monoxide greater than 0.3% (such as 1% or greater) can be used for short periods (e.g., one or a few breaths), depending upon the application.
- a gaseous carbon monoxide composition can be used to create an atmosphere that comprises carbon monoxide gas.
- An atmosphere that includes appropriate levels of carbon monoxide gas can be created, for example, by providing a vessel containing a pressurized gas comprising carbon monoxide gas, and releasing the pressurized gas from the vessel into a chamber or space to form an atmosphere that includes the carbon monoxide gas inside the chamber or space.
- the gases can be released into an apparatus that culminates in a breathing mask or breathing tube, thereby creating an atmosphere comprising carbon monoxide gas in the breathing mask or breathing tube, ensuring the patient is the only person in the room exposed to significant levels of carbon monoxide.
- Carbon monoxide levels in an atmosphere can be measured or monitored using any method known in the art. Such methods include electrochemical detection, gas chromatography, radioisotope counting, infrared abso ⁇ tion, colorimetry, and electrochemical methods based on selective membranes (see, e.g., Sunderman et al, Clin. Chem. 28:2026-2032, 1982; Ingi et al, Neuron 16:835-842, 1996). Sub-parts per million carbon monoxide levels can be detected by, e.g., gas chromatography and radioisotope counting.
- carbon monoxide levels in the sub-ppm range can be measured in biological tissue by a midinfrared gas sensor (see, e.g., Morimoto et al, Am. J. Physiol. Heart. Circ. Physiol 280:H482-H488, 2001). Carbon monoxide sensors and gas detection devices are widely available from many commercial sources.
- a pharmaceutical composition comprising carbon monoxide can also be a liquid composition.
- a liquid can be made into a pharmaceutical composition comprising carbon monoxide by any method known in the art for causing gases to become dissolved in liquids.
- the liquid can be placed in a so-called "C0 2 incubator” and exposed to a continuous flow of carbon monoxide, preferably balanced with carbon dioxide, until a desired concentration of carbon monoxide is reached in the liquid.
- carbon monoxide gas can be "bubbled” directly into the liquid until the desired concentration of carbon monoxide in the liquid is reached. The amount of carbon monoxide that can be dissolved in a given aqueous solution increases with decreasing temperature.
- an appropriate liquid can be passed through tubing that allows gas diffusion, where the tubing runs through an atmosphere comprising carbon monoxide (e.g., utilizing a device such as an extraco ⁇ oreal membrane oxygenator).
- the carbon monoxide diffuses into the liquid to create a liquid carbon monoxide composition.
- the liquid can be any liquid known to those of skill in the art to be suitable for administration to patients (see, for example, Oxford Textbook of Surgery, Morris and Malt, Eds., Oxford University Press, 1994). h general, the liquid will be an aqueous solution. Examples of solutions include Phosphate Buffered Saline (PBS), CelsiorTM, PerfadexTM, Collins solution, citrate solution, and University of Wisconsin (UW) solution (Oxford Textbook of Surgery, Morris and Malt, Eds., Oxford University Press, 1994).
- PBS Phosphate Buffered Saline
- CelsiorTM CelsiorTM
- PerfadexTM PerfadexTM
- Collins solution Collins solution
- citrate solution citrate solution
- UW University of Wisconsin
- the present invention contemplates that compounds that release CO into the body after administration of the compound (e.g., CO-releasing compounds, e.g., photoactivatable CO-releasing compounds), e.g., dimanganese decacarbonyl, tricarbonyldichlororuthenium (II) dimer, and methylene chloride (e.g., at a dose of between 400 to 600 mg/kg, e.g., about 500mg/kg), can also be used in the methods of the present invention, as can carboxyhemoglobin and CO-donating hemoglobin substitutes.
- Agents capable of delivering doses of CO gas or liquid can also be utilized (e.g., CO releasing gums, creams, ointments or patches)
- Any suitable liquid can be saturated to a set concentration of carbon monoxide via gas diffusers.
- pre-made solutions that have been quality controlled to contain set levels of carbon monoxide can be used. Accurate control of dose can be achieved via measurements with a gas permeable, liquid impermeable membrane connected to a carbon monoxide analyzer. Solutions can be saturated to desired effective concentrations and maintained at these levels.
- a patient can be treated with a carbon monoxide composition by any method known in the art of administering gases and/or liquids to patients.
- the present invention contemplates the systemic administration of liquid or gaseous carbon monoxide compositions to patients (e.g., by inhalation and/or ingestion), and the topical administration of the compositions to the patient's organs, e.g., the gastrointestinal tract.
- Gaseous carbon monoxide compositions are typically administered by inhalation through the mouth or nasal passages to the lungs, where the carbon monoxide can exert its effect directly or be readily absorbed into the patient's bloodstream.
- concentration of active compound (CO) utilized in the therapeutic gaseous composition will depend on abso ⁇ tion, distribution, inactivation, and excretion (generally, through respiration) rates of the carbon monoxide as well as other factors known to those of skill in the art. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed invention.
- Acute, sub-acute and chronic administration of carbon monoxide are contemplated by the present invention, depending upon, e.g., the severity or persistence of disease or condition in the patient.
- Carbon monoxide can be delivered to the patient for a time (including indefinitely) sufficient to treat the condition and exert the intended pharmacological or biological effect.
- Examples of methods and devices that can be utilized to administer gaseous pharmaceutical compositions comprising carbon monoxide to patients include ventilators, face masks and tents, portable inhalers, intravenous artificial lungs (see, e.g., Hattler et al, Artif. Organs 18(11):806-812, 1994; and Golob et al, ASAIO J., 47(5):432-437, 2001), and normobaric chambers, as described in-further detail below.
- the present invention further contemplates that aqueous solutions comprising carbon monoxide can be created for systemic delivery to a patient, e.g., by oral delivery to a patient.
- carbon monoxide compositions can be applied directly to the organs of a patient.
- carbon monoxide compositions can be applied to the interior and/or exterior of the entire gastrointestinal tract, or to any portion thereof, by any method known in the art for insufflating gases into a patient.
- gases e.g., carbon dioxide
- gases are often insufflated into the gastrointestinal tract and the abdominal cavity of patients to facilitate examination during endoscopic and laproscopic procedures, respectively (see, e.g., Oxford Textbook of Surgery, Morris and Malt, Eds., Oxford University Press, 1994).
- the skilled practitioner will appreciate that similar procedures could be used to administer carbon monoxide compositions directly to the gastrointestinal tract of a patient.
- Aqueous carbon monoxide compositions can also be administered directly to the organs of a patient.
- Aqueous forms of the compositions can be administered by any method known in the art for administering liquids to patients.
- the aqueous form can be administered orally, e.g., by causing the patient to ingest an encapsulated or unencapsulated dose of the aqueous carbon monoxide composition.
- liquids e.g., saline solutions
- saline solutions can be injected into the gastrointestinal tract and the abdominal cavity of patients during endoscopic and laparoscopic procedures, respectively. The skilled practitioner will appreciate that similar procedures could be used to admister liquid carbon monoxide compositions directly to the organs of a patient.
- Combination Therapy contemplates that any of the treatments described herein, e.g., induction/expression/administration of HO-1 and/or ferritin, and the administration of CO, bilirubin, and/or biliverdin, can be used individually or in any combination in surgical procedures and to treat the disorders or conditions described herein. Further, the present invention contemplates that in any treatment regimen using any combination of the herein-described treatments, the treatments can be administered simultaneously on a single or multiple occasions, and/or individually at varying points in time, e.g., at different phases of a disease or condition. For example, a patient can receive both bilirubin and iron, or both of those plus CO, or bilirubin plus ferritin, or two or more inducers of HO-1.
- a patient can be treated with pharmaceutical compositions described herein by any method known in the art of administering liquids, solids, and/or gases to a patient.
- Systemic Delivery of Pharmaceutical Compositions Aqueous and Solid Pharmaceutical Compositions
- aqueous pharmaceutical compositions can be created for systemic delivery to a patient by injection into the body, e.g., intravenously, intra-arterially, intraperitoneally, and/or subcutaneously.
- Aqueous pharmaceutical compositions can also be prepared for oral delivery, e.g., in encapsulated or unencapsulated form, to be absorbed in any portion of the gastrointestinal tract, e.g., the stomach or small intestine.
- solid pharmaceutical compositions can be created for systemic delivery to a patient, e.g., in the form of a powder or an ingestible capsule.
- Aqueous and solid pharmaceutical compositions typically include the active ingredient and a pharmaceutically acceptable carrier.
- pharmaceutically acceptable carrier includes solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and abso ⁇ tion delaying agents, and the like, compatible with pharmaceutical administration. Supplementary active compounds can also be inco ⁇ orated into the compositions.
- a pharmaceutical composition is formulated to be compatible with its intended route of administration.
- routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral and/or rectal administration.
- Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
- the parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
- compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
- suitable carriers include physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, NJ) or phosphate buffered saline (PBS).
- the composition must be sterile and should be fluid to the extent that easy syringability exists. It should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol, and the like), and suitable mixtures thereof.
- the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
- Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
- isotonic agents e.g., sugars, polyalcohols such as mannitol or sorbitol, or sodium chloride can be included in the composition.
- Prolonged abso ⁇ tion of the injectable compositions can be brought about by including in the composition an agent which delays abso ⁇ tion, for example, aluminum monostearate and gelatin.
- Microbeads, microspheres, or any other physiologicially-acceptable methods, e.g., encapsulation, can be used to delay release or abso ⁇ tion of the active ingredients.
- Sterile injectable solutions can be prepared by inco ⁇ orating the active ingredient in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.
- dispersions are prepared by inco ⁇ orating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above.
- the preferred methods of preparation' are vacuum drying, and freeze-drying that yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- Oral compositions which can be aqueous or solid, generally include an inert diluent or an edible carrier.
- the active compound can be inco ⁇ orated with excipients and used in the form of tablets, troches, or capsules, e.g., gelatin capsules.
- Pharmaceutically compatible binding agents and/or adjuvant materials can be included as part of the composition.
- the tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose; a disintegrating agent such as alginic acid, PrimogelTM, or corn starch; a lubricant such as magnesium stearate or sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
- a binder such as microcrystalline cellulose, gum tragacanth or gelatin
- an excipient such as starch or lactose
- a disintegrating agent such as alginic acid, PrimogelTM, or corn starch
- a lubricant such as magnesium stearate or sterotes
- a glidant such as colloidal silicon dioxide
- Systemic administration can also be by transmucosal or transdermal means.
- penetrants appropriate to the barrier to be permeated are used in the formulation.
- penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives.
- Transmucosal administration can be accomplished through the use of nasal sprays or suppositories.
- the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.
- the compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.
- suppositories e.g., with conventional suppository bases such as cocoa butter and other glycerides
- retention enemas for rectal delivery.
- the active ingredients can be prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
- a controlled release formulation including implants and microencapsulated delivery systems.
- Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art.
- the materials can also be obtained commercially from Alza Co ⁇ oration and Nova Pharmaceuticals, Inc.
- Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies specific for viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.
- Dosage unit form refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
- Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population).
- the dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50.
- the data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans.
- the dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity.
- the dosage can vary within this range depending upon the dosage form employed and the route of administration utilized.
- the therapeutically effective dose can be estimated initially from cell culture assays.
- a dose can be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture.
- IC50 i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms
- levels in plasma can be measured, for example, by high performance liquid chromatography.
- Gaseous pharmaceutical compositions e.g., pharmaceutical compositions containing carbon monoxide
- the following methods and apparatus for administering carbon monoxide compositions are illustrative of useful systemic delivery methods for the gaseous pharmaceutical compositions described herein.
- Medical grade carbon monoxide can be purchased mixed with air or another oxygen-containing gas in a standard tank of compressed gas (e.g., 21% O 2 , 79% N 2 ). It is non-reactive, and the concentrations that are required for the methods of the present invention are well below the combustible range (10% in air).
- the gas presumably will be delivered to the bedside where it will be mixed with house air in a blender to a desired concentration in ppm (parts per million).
- the patient will inhale the gas mixture through a ventilator, which will be set to a flow rate based on patient comfort and needs. This is determined by pulmonary graphics (i.e., respiratory rate, tidal volumes etc.).
- Fail-safe mechanism(s) to prevent the patient from unnecessarily receiving greater than desired amounts of carbon monoxide can be designed into the delivery system.
- the patient's carbon monoxide level can be monitored by studying (1) carboxyhemoglobin (COHb), which can be measured in venous blood, and (2) exhaled carbon monoxide collected from a side port of the ventilator.
- COHb carboxyhemoglobin
- Carbon monoxide exposure can be adjusted based upon the patient's health status and on the basis of the markers. If necessary, carbon monoxide can be washed out of the patient by switching to 100% O 2 inhalation. Carbon monoxide is not metabolized; thus, whatever is inhaled will ultimately be exhaled except for a very small percentage that is converted to CO 2 .
- Carbon monoxide can also be mixed with any level of O 2 to provide therapeutic delivery of carbon monoxide without consequential hypoxic conditions.
- a carbon monoxide containing gas mixture is prepared as above to allow passive inhalation by the patient using a facemask or tent.
- the concentration inhaled can be changed and can be washed out by simply switching over to 100% O 2 .
- Monitoring of carbon monoxide levels would occur at or near the mask or tent with a fail-safe mechanism that would prevent too high of a concentration of carbon monoxide from being inhaled.
- Compressed carbon monoxide can be packaged into a portable inhaler device and inhaled in a metered dose, for example, to permit intermittent treatment of a recipient who is not in a hospital setting.
- Different concentrations of carbon monoxide could be packaged in the containers.
- the device could be as simple as a small tank (e.g., under 5 kg) of appropriately diluted CO with an on-off valve and a tube from which the patient takes a whiff of CO according to a standard regimen or as needed.
- An artificial lung designed for O 2 delivery and CO 2 removal can be used for carbon monoxide delivery.
- the catheter when implanted, resides in one of the large veins and would be able to deliver carbon monoxide at given concentrations either for systemic delivery or at a local site.
- the delivery can be a local delivery of a high concentration of carbon monoxide for a short period of time at the site of the procedure, e.g., in proximity to the small intestine (this high concentration would rapidly be diluted out in the bloodstream), or a relatively longer exposure to a lower concentration of carbon monoxide (see, e.g., Hattler et al, Artif. Organs 18(11):806-812, 1994; and Golob et al, ASAIO J., 47(5):432-437, 2001).
- the patient would be inside an airtight chamber that would be flooded with carbon monoxide (at a level that does not endanger the patient, or at a level that poses an acceptable risk, or for non-human donors or brain-dead donors, at any desired level) without the risk of bystanders being exposed.
- the chamber could be flushed with air (e.g., 21% O 2 , 79%) N 2 ) and samples could be analyzed by carbon monoxide analyzers to ensure no carbon monoxide remains before allowing the patient to exit the exposure system.
- compositions can be applied directly to an organ, tissue, or area of the patient's body to be treated.
- Aqueous and solid pharmaceutical compositions can also be directly applied to an organ of a patient, or to an area of the patient targeted for treatment, by any method known in the art for administering liquids or solids to patients.
- an aqueous or solid composition can be administered orally, e.g., by causing the patient to ingest an encapsulated or unencapsulated dose of the aqueous or solid pharmaceutical composition, to treat the interior of the gastrointestinal tract or any portion thereof.
- liquids e.g., saline solutions
- saline solutions are often injected into the gastrointestinal tract and the abdominal cavity of patients during endoscopic and laparoscopic procedures, respectively.
- similar procedures could be used to administer aqueous pharmaceutical compositions directly to an organ or e.g., in the vicinity of an organ to be treated, to thereby expose the organ in situ to an aqueous pharmaceutical composition.
- in situ exposures can be performed by any method known in the art, e.g., by in situ flushing of the organ with a liquid pharmaceutical composition prior to removal from the donor (see Oxford Textbook of Surgery, Morris and Malt, Eds., Oxford University Press, 1994). Such exposures are described in further detail below.
- Gaseous pharmaceutical compositions can be directly applied to an organ of a patient, or to an area of the patient targeted for treatment, by any method known in the art for insufflating gases into a patient.
- gases e.g., carbon dioxide
- gases are often insufflated into the gastrointestinal tract and the abdominal cavity of patients to facilitate examination during endoscopic and laparoscopic procedures, respectively (see, e.g., Oxford Textbook of Surgery, Morris and Malt, Eds., Oxford University
- gaseous pharmaceutical compositions can be insufflated into the abdominal cavity of patients, e.g., in the vicinity of an organ to be treated, to thereby expose the organ in situ to a gaseous pharmaceutical composition.
- the present invention contemplates the use of the methods described herein to treat patients who undergo transplantation.
- the methods can be used to treat donors, recipients and/or the organ at any step of the organ harvesting, storage, and transplant process.
- an organ can be harvested from a donor, treated with a pharmaceutical composition ex vivo in accordance with the present invention, and transplanted into a recipient.
- the organ can be treated in situ, while still in the donor (by treatment of the donor or by treating the organ).
- a pharmaceutical composition can be admimstered to the recipient prior to, during, and/or after the surgery, e.g., after the organ is reperfused with the recipient's blood.
- the composition can be administered to the donor prior to or during the process of harvesting the organ from the donor.
- transplantation is used throughout the specification as a general term to describe the process of transferring an organ to a patient.
- transplantation is defined in the art as the transfer of living tissues or cells from a donor to a recipient, with the intention of maintaining the functional integrity of the transplanted tissue or cells in the recipient (see, e.g., The Merck Manual, Berkow, Fletcher, and Beers, Eds., Merck Research Laboratories, Rahway, NJ., 1992).
- the term includes all categories of transplants known in the art. Transplants are categorized by site and genetic relationship between donor and recipient.
- the term includes, e.g., autotransplantation (removal and transfer of cells or tissue from one location on a patient to the same or another location on the same patient), allotransplantation (transplantation between members of the same species), and xenotransplantation (transplantations between members of different species).
- donor or “donor patient” as used herein refers to an animal (human or non-human) from whom an organ or tissue can be obtained for the pu ⁇ oses of storage and/or transplantation to a recipient patient.
- recipient or “recipient patient” refers to an animal (human or non-human) into which an organ or tissue can be transferred.
- organ rejection is art- recognized, and are used throughout the specification as a general term to describe the process of rejection of an organ, tissues, or cells in a recipient. Included within the definition are, for example, three main patterns of rejection that are usually identified in clinical practice: hyperacute rejection, acute rejection, and chronic rejection (see, e.g., Oxford Textbook of Surgery, Morris and Malt, Eds., Oxford University Press, 1994).
- organs is used throughout the specification as a general term to describe any anatomical part or member having a specific function in the animal. Further included within the meaning of this term are substantial portions of organs, e.g., cohesive tissues obtained from an organ. Further still, included within the meaning of this term are portions of an organ as small as one cell of the organ. Such organs include but are not limited to kidney; liver; heart; intestine, e.g., large or small intestine; pancreas, e.g., islets; and lungs. Further included in this definition are bones, skin, and blood vessels.
- Ex vivo exposure of an organ to a pharmaceutical composition can occur by exposing the organ to an atmosphere comprising a gaseous pharmaceutical composition, to a liquid pharmaceutical composition, e.g., a liquid perfusate, storage solution, or wash solution containing the pharmaceutical composition, or to both.
- a liquid pharmaceutical composition e.g., a liquid perfusate, storage solution, or wash solution containing the pharmaceutical composition, or to both.
- the exposure can be performed in any chamber or area suitable for creating an atmosphere that includes appropriate levels of carbon monoxide gas.
- chambers include, for example, incubators and chambers built for the prapose of accommodating an organ in a preservation solution.
- An appropriate chamber can be a chamber wherein only the gases fed into the chamber are present in the internal atmosphere, such that the concentration of carbon monoxide can be established and maintained at a given concentration and purity, e.g., where the chamber is airtight.
- a CO 2 incubator can be used to expose an organ to a carbon monoxide composition, wherein carbon monoxide gas is supplied in a continuous flow from a vessel that contains the gas.
- the exposure can be performed in any chamber or space having sufficient volume for submerging the organ, completely or partially, in an aqueous pharmaceutical composition.
- the organ can be exposed by placing the organ in any suitable container, and causing a liquid pharmaceutical composition to "wash over" the organ, such that the organ is exposed to a continuous flow of the composition.
- the organ can be perfused with an aqueous pharmaceutical composition.
- perfusion is an art-recognized term, and relates to the passage of a liquid, e.g., an aqueous pharmaceutical composition, through the blood vessels of the organ. Methods for perfusing organs ex vivo and in situ are well known in the art.
- An organ can be perfused with an aqueous pharmaceutical composition ex vivo, for example, by continuous hypothermic machine perfusion (see Oxford
- the aqueous pharmaceutical solution can be allowed to remain in the vasculature for a given length of time.
- the organ in in situ or ex vivo perfusions, can be perfused with a wash solution, e.g., UW solution without a pharmaceutical composition, prior to perfusion with the aqueous pharmaceutical composition to remove the donor's blood from the organ.
- a wash solution e.g., UW solution without a pharmaceutical composition
- the wash solution itself can be a pharmaceutical composition, e.g., a pharmaceutical composition comprising carbon monoxide.
- the organ in the context of pharmaceutical compositions comprising carbon monoxide, can be placed, e.g., submerged, in a medium or solution that does not include carbon monoxide, and placed in a chamber such that the medium or solution can be made into a carbon monoxide composition via exposure to a carbon monoxide-containing atmosphere as described herein.
- the organ can be submerged in a liquid that does not include carbon monoxide, and carbon monoxide can be "bubbled" into the liquid.
- An organ can be harvested from a donor, and transplanted by any methods known to those of skill in the art (see, for example, Oxford Textbook of Surgery, Morris and Malt, Eds., Oxford University Press, 1994). The skilled practitioner will recognize that methods for transplanting and/or harvesting organs for transplantation can vary depending upon many circumstances, such as the age of the donor/recipient or the nature of the organ being transplanted.
- the present invention contemplates that any or all of the above methods for exposing an organ to a pharmaceutical composition, e.g., washing, submerging, or perfusing, can be used in a given procedure, e.g., used in a single transplantation procedure.
- intimal hype ⁇ lasia is an art-recognized term and is used herein to refer to the proliferation of cells, e.g., smooth muscle cells and/or myofibroblasts, within the intima.
- intimal hype ⁇ lasia can be caused by any number of factors, e.g., mechanical, chemical and/or immunological damage to the intima.
- Intimal hype ⁇ lasia can often be observed in patients, for example, following balloon angioplasty or vascular surgery, e.g., vascular surgery involving vein grafts.
- angioplasty is an art-recognized term and refers to any procedure involving the remodeling of an artery. Such procedures include, e.g., angioplasty using balloons ("balloon angioplasty"), lasers (“laser angioplasty”), and any other mode for performing angioplasty, e.g., using other suitable instruments, such as a microfabricated probe.
- Individuals considered at risk for developing intimal hype ⁇ lasia may benefit particularly from the invention, primarily because prophylactic treatment can begin before there is any evidence of intimal hype ⁇ lasia.
- Individuals "at risk” include, e.g., patients that have or will undergo angioplasty, e.g., balloon angioplasty, or patients that have or will have any type of mechanical, chemical and/or immunological damage to the intima.
- a patient can be treated according to the methods of the present invention before, during and/or after the surgical procedure or angioplasty.
- vein(s) can be exposed to the pharmaceutical compositions described herein in situ and/or ex vivo, as described herein in the context of organ transplants.
- the vein can be exposed to a gaseous pharmaceutical composition, and/or to a liquid pharmaceutical composition, e.g., a liquid perfusate, storage solution, or wash solution having the active ingredient dissolved therein.
- a liquid pharmaceutical composition can be instilled into an arterial segment, e.g., by retrograde perfusion, and can be allowed to remain in the segment for a given length of time.
- the methods of the present invention can be used to treat one or more of the following inflammatory, respiratory, cardiovascular, renal, hepatobiliary, reproductive, and gastrointestinal disorders; shock; or cellular proliferative and/or differentiative disorders, or to reduce the effects of ischemia, or aid in wound healing.
- Respiratory Disorders include inflammatory, respiratory, cardiovascular, renal, hepatobiliary, reproductive, and gastrointestinal disorders; shock; or cellular proliferative and/or differentiative disorders, or to reduce the effects of ischemia, or aid in wound healing.
- respiratory conditions include, but are not limited to, asthma; Acute Respiratory Distress Syndrome (ARDS), e.g., ARDS caused by peritonitis, pneumonia (bacterial or viral), or trauma; idiopathic pulmonary diseases; interstitial lung diseases, e.g., Interstitial Pulmonary Fibrosis (IPF); pulmonary emboli; Chronic Obstructive Pulmonary Disease (COPD); emphysema; bronchitis; cystic fibrosis; lung cancer of any type; lung injury, e.g., hyperoxic lung injury; Primary Pulmonary
- ARDS Acute Respiratory Distress Syndrome
- ARDS e.g., ARDS caused by peritonitis, pneumonia (bacterial or viral), or trauma
- idiopathic pulmonary diseases e.g., Interstitial Pulmonary Fibrosis (IPF); pulmonary emboli; Chronic Obstructive Pulmonary Disease (COPD); emphysema; bronchitis;
- PPH Hypertension
- secondary pulmonary hypertension e.g., secondary pulmonary hypertension
- sleep-related disorders e.g., sleep apnea.
- Cardiovascular disorders include disorders involving the cardiovascular system, e.g., the heart, the blood vessels, and/or the blood.
- a cardiovascular disorder can be caused, for example, by an imbalance in arterial pressure, a malfunction of the heart, or an occlusion of a blood vessel, e.g., by a thrombus.
- Examples of such disorders include congestive heart failure, peripheral vascular disease, pulmonary vascular thrombotic diseases such as pulmonary embolism, stroke, ischemia- reperfusion (I/R) injury to the heart, atherosclerosis, and heart attacks.
- Renal Disorders include congestive heart failure, peripheral vascular disease, pulmonary vascular thrombotic diseases such as pulmonary embolism, stroke, ischemia- reperfusion (I/R) injury to the heart, atherosclerosis, and heart attacks.
- Renal Disorders Renal Disorders
- Disorders involving the kidney include, but are not limited to, pathologies of glomemlar injury such as in situ immune complex deposition and cell-mediated immunity in glomerulonephritis; damage caused by activation of alternative complement pathway; epithelial cell injury; pathologies involving mediators of glomemlar injury including cellular and soluble mediators; acute glomemlonephritis, such as acute proliferative glomemlonephritis, e.g., poststreptococcal glomemlonephritis and nonstreptococcal acute glomemlonephritis, rapidly progressive glomemlonephritis, nephrotic syndrome, membranous glomemlonephritis (membranous nephropathy), minimal change disease (lipoid nephrosis), focal segmental glomerulosclerosis, membranoproliferative glomemlonephritis, Ig
- Disorders involving the liver include, but are not limited to, cirrhosis and infectious disorders such as viral hepatitis, including hepatitis A-E viral infection and infection by other hepatitis viruses, clinicopathologic syndromes, acute viral hepatitis, chronic viral hepatitis, and fulminant hepatitis; and drag- and toxin-induced liver disease, such as alcoholic liver disease.
- infectious disorders such as viral hepatitis, including hepatitis A-E viral infection and infection by other hepatitis viruses, clinicopathologic syndromes, acute viral hepatitis, chronic viral hepatitis, and fulminant hepatitis
- drag- and toxin-induced liver disease such as alcoholic liver disease.
- Gastrointestinal disorders include, but are not limited to, ileus (of any portion of the gastrointestinal tract, e.g., the large or small intestine); inflammatory bowel disease, e.g., specific inflammatory bowel disease, e.g., infective specific inflammatory bowel disease, e.g., amoebic or bacillary dysentery, schistosomiasis, campylobacter enterocolitis, yersinia enterocolitis, or enterobius vermicularis; non- infective specific inflammatory bowel disease, e.g., radiation enterocolitis, ischaemic colitis, or eosinophilic gastroenteritis; non-specific bowel disease, e.g., ulcerative colitis, indeterminate colitis, and Crohn's disease; necrotizing enterocolitis (NEC); and pancreatitis.
- ileus of any portion of the gastrointestinal tract, e.g., the large or small intestine
- cellular proliferative and/or Differentiative disorders include, but are not limited to, cancer, e.g., carcinoma, sarcoma, metastatic disorders or hematopoietic neoplastic disorders, e.g., leukemias.
- a metastatic tumor can arise from a multitude of primary tumor types, including but not limited to those of prostate, colon, lung, breast and liver origin.
- cancer refers to cells having the capacity for autonomous growth. Examples of such cells include cells having an abnormal state or condition characterized by rapidly proliferating cell growth. The term is meant to include all types of cancerous growths, e.g., tumors, or oncogenic processes, or metastatic tissues.
- malignancies of the various organ systems such as lung, breast, thyroid, lymphoid, gastrointestinal, and genito-urinary tract
- adenocarcinomas which include malignancies such as most colon cancers, renal-cell carcinoma, prostate cancer and/or testicular tumors, non-small cell carcinoma of the lung, cancer of the small intestine and cancer of the esophagus.
- the term "carcinoma” is art recognized and refers to malignancies of epithelial or endocrine tissues including respiratory system carcinomas, gastrointestinal system carcinomas, genitourinary system carcinomas, testicular carcinomas, breast carcinomas, prostatic carcinomas, endocrine system carcinomas, and melanomas.
- Exemplary carcinomas include those forming from tissue of the cervix, lung, prostate, breast, head and neck, colon and ovary.
- the term also includes carcinosarcomas, e.g., which include malignant tumors composed of carcinomatous and sarcomatous tissues.
- An "adenocarcinoma” refers to a carcinoma derived from glandular tissue or in which the tumor cells form recognizable glandular structures.
- the term “sarcoma” is art recognized and refers to malignant tumors of mesenchymal derivation.
- hematopoietic neoplastic disorders includes diseases involving hype ⁇ lastic/neoplastic cells of hematopoietic origin.
- a hematopoietic neoplastic disorder can arise from myeloid, lymphoid or erythroid lineages, or precursor cells thereof.
- Cancers which can be treated using the present compositions and methods include, for example, stomach, colon, rectal, liver, pancreatic, lung, breast, cervix uteri, co ⁇ us uteri, ovary, prostate, testis, bladder, renal, brain/central nervous system, head and neck, throat, Hodgkins disease, non-Hodgkins leukemia, skin melanoma, various sarcomas, small cell lung cancer, choriocarcinoma, mouth/pharynx, esophagus, larynx, melanoma, and kidney and lymphoma, among others.
- Neurological Disorders include, for example, stomach, colon, rectal, liver, pancreatic, lung, breast, cervix uteri, co ⁇ us uteri, ovary, prostate, testis, bladder, renal, brain/
- Neurological disorders include, but are not limited to disorders involving the brain, e.g., degenerative diseases affecting the cerebral cortex, including Alzheimer's disease, and degenerative diseases of basal ganglia and brain stem, including Parkinsonism and idiopathic Parkinson's disease (paralysis agitans). Further, the methods can be used to treat pain disorders.
- pain disorders include, but are not limited to, pain response elicited during various forms of tissue injury, e.g., inflammation, infection, and ischemia, usually referred to as hyperalgesia (described in, for example, Fields, Pain, New
- musculoskeletal disorders e.g., joint pain; tooth pain; headaches; pain associated with surgery; pain related to irritable bowel syndrome; or chest pain.
- seizure disorders e.g., epilepsy. Inflammatory Disorders
- the methods of the present invention can be used to treat inflammatory disorders.
- inflammatory disorder(s) and “inflammation” are used to describe the fundamental pathological process consisting of a dynamic complex of reactions (which can be recognized based on cytologic and histologic studies) that occur in the affected blood vessels and adjacent tissues in response to an injury or abnormal stimulation caused by a physical, chemical or biologic agent, including the local reactions and resulting mo ⁇ hologic changes, the destruction or removal of the injurious material, and the responses that lead to repair and healing.
- Inflammation is characterized in some instances by the infiltration of cells immune cells such as monocytes/macrophages, natural killer cells, and/or lymphocytes (e.g., B and T lymphocytes) into the area of tissue.
- inflamed tissue may contain cytokines and chemokines that are produced by the cells that have infiltrated into the area.
- inflammation is accompanied by thrombosis, including both coagulation and platelet aggregation.
- the term inflammation includes various types of inflammation such as acute, chronic, allergic (including conditions involving mast cells), alterative (degenerative), atrophic, catarrhal (most frequently in the respiratory tract), croupous, fibrinopuralent, fibrinous, immune, hype ⁇ lastic or proliferative, subacute, serous and serofibrinous.
- Inflammation localized in the gastrointestinal tract, or any portion thereof, kidneys, liver, heart, skin, spleen, brain, kidney, pulmonary tract, and the lungs is favorably treated by the methods of the present invention
- h flammation associated with shock e.g., septic shock, hemorrhagic shock caused by any type of trauma
- anaphylactic shock is favorably treated by the methods of the present invention.
- the methods of the present invention can be used to treat rheumatoid arthritis, lupus, and other inflammatory and/or autoimmune diseases, heightened inflammatory states due to immunodeficiency, e.g., due to infection with HIV, and hypersensitivities.
- the present invention contemplates that the methods described herein can be used to promote wound healing (e.g., in transplanted, lacerated (e.g., due to surgery), or burned skin). They would typically be applied locally to the wound (e.g., as a wound dressing, lotion, or ointment), but could be delivered systemically as well.
- wound healing e.g., in transplanted, lacerated (e.g., due to surgery), or burned skin. They would typically be applied locally to the wound (e.g., as a wound dressing, lotion, or ointment), but could be delivered systemically as well.
- the present invention contemplates that the methods described herein can also be used to treat or prevent certain reproductive disorders, e.g., impotence and/or inflammation associated with sexually transmitted diseases. Further, the methods of the present invention can be used to prevent premature uterine contractions, and can be used to prevent premature deliveries and menstrual cramps. EXAMPLES The invention is illustrated in part by the following examples, which is not to be taken as limiting the invention in any way.
- mice Pathogen-free male C57BL/6 mice, 4-6 weeks of age (Taconic; C57BL/6X129 svj strain) were used in this example. Mice were kept for one week at 4 mice/cage and fed normal laboratory chow and drinking water ad libitum prior to the experiments. All mice weighed between 22.5 g and 27.7 g at the beginning of the trial. The animal experimentation protocol was reviewed and approved by the Animal Care and Use Committees of the Beth Israel Deaconess Medical Center. Induction of Colitis.
- Colitis was induced by feeding mice 5% (wt/v) dextran sodium sulfate (DSS) (MW 40,000; ICN Biomedicals Inc., OH), dissolved in distilled water, for a period of 7 days. The resulting condition was termed "DSS-colitis.” Control animals were fed distilled water ad libitum. The mortality rate in the control group and the CO-treated group was 10% (2/20) and 14% (2/14), respectively. These animals were excluded from the statistical analysis. In the other groups, no mortality occurred during 7 days of 5% DSS treatment.
- DSS dextran sodium sulfate
- CoPPIX Cobalt protopo ⁇ hyrin
- ZnPPIX zinc protopo ⁇ hyrin
- biliverdin dihydrochloride ICN Biomedicals Inc., OH
- CoPPIX 5 mg/kg
- biliverdin 50 ⁇ mol/kg
- DFO Desferoxamine
- CO gas was administrated exogenously by putting animals in a CO exposure chamber (Otterbein et al., Nat. Med. 6(4):422-8, 2000). Briefly, CO at a concentration of 1% (10,000 parts per million (ppm)) in compressed air was mixed with balanced air (21% oxygen) in a stainless steel mixing cylinder before entering the exposure chamber. CO concentrations were controlled by varying the flow rates of CO in a mixing cylinder before delivery to the chamber. Because the flow rate is primarily determined by the O 2 flow, only the CO flow was changed to deliver the final concentration to the exposure chamber. A CO analyzer (InterScan Co ⁇ oration, Chatsworth, CA) was used to measure CO levels continuously in the chamber.
- mice were placed in the chamber 24 hours before the induction of the colitis and were kept in the exposure chamber during the whole period of the experiment (total of 8 days). CO concentration was maintained between 250 and 400 ppm at all times. Animals were removed daily from the chamber to assess weight and stool.
- the animals were sacrificed, and the whole colon from the colo-cecal junction to the anal verge was removed and gently cleaned of stool.
- the distal part of the colon was fixed in 10% formaldehyde and embedded in paraffin for staining with hematoxylin and eosin.
- the transverse sections were graded in blinded fashion for severity of mucosal injury on a scale of 0-4 as follows: Grade 0: intact crypt; Grade 1: loss of the basal one-third of the crypt; Grade 2: loss of the basal two-thirds of the crypt; Grade 3: loss of the entire crypt with the surface epithelium remaining intact; Grade 4: loss of both crypt and surface epithelium (erosion).
- Proteins were then detected with rabbit polyclonal antibodies directed against human HO-1 (StressGen, Victoria, Canada) or ⁇ -tubulin (Boehringer Mannheim, Mannheim, Germany). Proteins were visualized using HRP-conjugated donkey anti-rabbit IgG or goat anti-mouse IgG (Pierce) and the ECL assay (Amersham Life Science, Arlington Heights, IL), according to manufacturer's instructions.
- the primers for murine and human HOI (5' : TGA AGG AGG CCA CCA AGG AGG T (SEQ ID NO:l); 3': AGG TCA CCC AGG TAG CGG GT (SEQ ID NO:2)) and ⁇ -actin (525bp) (5': GCC ATC CTG CGT CTG GAC CTG G(SEQ ID NO:3); 3': TAC TCC TGC TTG CTG ATC CAC A (SEQ ID NO:4)) were obtained from Life Technologies, NY, USA.
- PCR reactions were performed after a 4 min denaturation at 94°C a repeating the cycle 94°C, 55°C and 72°C each for 1 min for number of cycles specific for each primer pair in a Peltier Thermal Cycler PTC-200 (MJ Research, Las Vegas, NV, USA). PCR products (10-20 ⁇ l) were analyzed in an ethidium bromide- stained 1% agarose gel.
- DSS Induces Acute Hemorrhagic Colitis and HO-1 Expression.
- the C57/BL6 mice exposed to 5% DSS in the drinking water showed the first clinical symptoms by days 2 and 3, with the development of loose stools and hemoccult positive stools.
- days 5 to 6 most of the animals developed the complete picture of a hemorrhagic colitis with diarrhea and gross bleeding, hi the control group, 2 deaths occurred (out of 20 subjects, 10%) before the termination of the 7-day trial. Both of these mortalities occurred on day 6. These animals were excluded from the statistical analysis.
- the CoPP-freated animals showed consistently high levels of HO-1 protein in the intestine over the entire 7 day period of the experiment, whereas non-treated animals exhibited slowly increasing HO-1 levels that reached a maximum at day 7 (Figs. 2A and 2B versus Figs. 1A and IB).
- the level of HO-1 in the non-treated animals at day 7 was below the level of HO-1 observed in the CoPP-freated animals.
- HO-1 Induction Ameliorates DSS-Colitis and Reduces Associated Colonic Lesions.
- the constant induction of HO-1 by CoPP treatment ameliorated DSS-colitis as observed clinically and mo ⁇ hologically.
- Fig. 6A Using light microscopy, it was observed that the biliverdin treatment group had a preserved cryptal structure (Fig. 6A). The crypt score was also significantly better in comparison to the non-treatment group (3 versus 4.8; p ⁇ 0.05; Fig. 6B).
- biliverdin did not mediate protection to the same extent as CoPP/HO-1, but the difference between the effects of CoPP/HO-1 and biliverdin did not reach significance.
- upregulation of HO-1 e.g., by administration of CoPP or biliverdin, alone or in combination with CO, is useful in the treatment of colonic inflammation, e.g., colitis and associated colonic lesions.
- mice Male DBA/2 (H-2 d ), B6AF1 (H-2 k/d ' b ) and FVB (H-2 q ) mice were purchased from Jackson Lab. Inc. (Bar Harbor, ME). They were maintained in the institutional specific-pathogen free facility, which has an appropriate light cycle with free access to water and chow ad libitum, and used for experiments at age of 6-10 weeks.
- the heart graft was harvested from either DBA2/J (donor strain) or FVB (third-party strain) mice.
- the right jugular vein and the right common carotid artery of recipient were dissected, and a cuff (polyethylene or polyimide) was connected to these vessels.
- the graft aorta and pulmonary artery were sleeved over the cuff on the recipient's common carotid artery and the jugular vein, respectively, and fixed with a ligature.
- beating of the graft was monitored by daily palpation, and scored +1 to +4 according to the strength of graft contractions.
- Graft rejection was defined as cessation of beating, and was confirmed by direct inspection followed by histological examination.
- T cells and Culture Medium Primary murine leukocytes were isolated by mincing the spleen followed by osmotic lysis of red blood cells. T cells were further enriched by passing through a nylon-wool mesh column, and purified using the MACS Pan T cell isolation kit (Miltenyi Biotec Inc., Auburn, CA) according to the manufacture's instractions. Purity of CD3 + T cells was more than 95%, as determined by flow cytometry. The Jurkat cell line was maintained in RPMI 1640 culture media (Bio Whittaker Inc., Walkersville, MD) supplemented with 2 mM 1-glutamine, 100 U/ml penicillin, 100 ⁇ g/ml streptomycin, and 10%o fetal calf serum. For murine primary cell culture, 2-ME (50 ⁇ M) was also added to the media. Experimental Reagents and Treatment Protocol. Cobalt protopo ⁇ hyrin
- Donor and recipient mice were treated either with CoPPIX (5 mg/kg/day), ZnPPIX (5 mg/kg/day) or biliverdin (administered once, twice or three times per day at a dose of 50 ⁇ mol/kg/dose). All reagents were administered by intraperitoneal (i.p.) injection. Donor animals were treated for 2 days, starting from 2 days before graft harvest (day -2 and day -1). Treatment of recipient mice was initiated one day before transplantation, and continued until 13 days post-transplant (day-1 to day 13).
- DSI donor splenocyte infusion
- D-7 DSI (D-7)
- treatments of recipient animals either with CoPPIX or ZnPPIX
- day -8 days -7
- Recipients received no further treatment.
- Spleen cells (2x10 7 ) isolated from DBA/2J mice as described herein were used for DSI treatment. The cells were injected via the penile vein with 200 ⁇ l of 0.9% saline solution.
- Bilirubin assay Biliverdin at 50 ⁇ mol/kg was injected i.p. into B6AF1 mice. Blood was drawn before and 15, 30, 60, 120, 240, and 360 minutes after biliverdin injection. Serum was collected by centrifugation of blood samples, and the total bilirubin level was measured using a total bilirubin assay kit (Sigma Aldrich, St. Louis, MO). Measurement of total bilirubin was performed according to the kit protocol, and was duplicated for each sample. This experiment was repeated four times.
- Con A and anti-CD3 mAb mediated proliferation assay B6AF1 splenocytes or purified T cells were prepared according to the herein-described method and used as responder cells. Responders (2.5xl0 5 /well) were stimulated with either Con A (1 ⁇ g/ l) or anti-CD3 mAb (1 ⁇ g/ml) and cultured in a 96 well round bottom plates. Purified T cells (5xl0 4 /well) were cultured in anti-CD3 mAb (10 ⁇ g/ml) coated 96 well flat bottom plates in the presence of anti-CD28 mAb (1 ⁇ g/ml).
- Cells were cultured with or without biliverdin (at various concentrations) for 48 hours at 37°C, 95%o air with 5% CO . They were pulsed with 3 H-thymidine (1 ⁇ Ci/well) 16 hours before termination of cell culture and 3 H-thymidine inco ⁇ oration was measured by using a ⁇ -counter. These proliferation assays were performed in triplicate and were repeated 3 times.
- MLC Mixed lymphocyte culture
- CD3 mAb (1 ⁇ g/ml), and cultured in 96 well round bottom plates with or without biliverdin (50 or 100 ⁇ M). Forty-eight hours later, culture supernatant (100 ⁇ l) was collected and stored at " 80°C until use. All cultures were performed in triplicates. IL- 2 levels in the supernatants were measured by enzyme-linked immunosorbent assays (ELISA) using an IL-2 assay kit (Quantikine® M, R&D Systems, Inc), following kit instructions. Measurements of each supernatant sample for IL-2 were performed in duplicate. The experiment was repeated 4 times.
- ELISA enzyme-linked immunosorbent assays
- B6AF1 leukocytes (5x10 5 cells/well) were stimulated with anti-CD3 mAb (1 ⁇ g/ml) and cultured in 96 well round bottom plates with or without biliverdin (100 ⁇ M).
- biliverdin 100 ⁇ M.
- cells were harvested, washed, and stained with fluorochrome conjugated isotype control Abs, or specific anti-CD4 and/or anti-CD25 mAbs (all antibodies obtained from BD Pharmingen).
- Non-stimulated na ⁇ ve leukocytes were used as a negative control.
- Sample protein was then incubated with the reaction mixture containing rat liver cytosol, hemin, glucose-6-phosphate, glucose-6-phosphate dehydrogenase and NADP ⁇ (Sigma- Aldrich Co ⁇ oration, St. Louis, MO) for 60 minutes at 37°C.
- the generated bilimbin was measured by reacting with diazotized surfanilic acid to yield azobilimbin using spectrophotometer.
- HO-1 was detected using the rabbit anti- human HO-1 polyclonal antibody (Stress Gen Biotechnologies Co ⁇ ., Victoria, Canada); ⁇ -actin was detected using the goat anti-mouse ⁇ -actin mAb (1 A4, Sigma- Aldrich Co ⁇ oration). Primary antibodies were detected using horseradish peroxidase conjugated donkey anti-rabbit or goat anti-mouse IgG secondary antibodies (Pierce, Rockford, IL). Protein was visualized using the Enhanced Chemi Luminescence(ECLTM) Assay kit (Amersham Life Science Inc., Arlington Heights, IL), according to the manufacturer's instractions, and stored in the form of photo radiographs (BiomaxTM MS, Eastman Kodak, Rochester, NY). The amount of HO-1 expression was normalized with ⁇ -actin expression, and was quantified by using the hnageQuantTM software (Molecular Dynamics, Sunny Vale, CA).
- ECLTM Enhanced Chemi Luminescence
- Biomedicals in the presence or absence of 100 ⁇ M biliverdin. Following 0, 2, and 4 hrs of stimulation, cells (30xl0 6 cells for each group at each time points) were collected, washed twice with PBS, and pelleted. Nuclear and cytoplasmic extracts were prepared according to a modified Shapiro's method(Shapiro et al, DNA 7(l):47-55, 1988). Protein concentrations were determined by the Bradford assay.
- oligonucleotides were used for EMSA: NFAT, (coding) 5'-GCCCACAGAGGAAAATTTGTTTCATACAG-3'(SEQ ID NO:5), (non-coding) 5'-CTGTATGAAACAAATTTTCCTCTGTCCGC-3' (SEQ ID NO:6); and
- NF-KB (coding) 5'-AGCTTAGAGGGGACTTTCCGAGAGGA-3' (SEQ ID NO:7), (non-coding) 5'-TCCTCTCGGAAAGTC-CCCTCTAAGCT-3' (SEQ ID NO:8).
- Oligonucleotides were radioactively labeled with [ 32 P] ATP.
- the EMSA reactions were assembled as previously described (Usheva et al, Proc. Natl. Acad. Sci. USA 93(24): 13571-6, 1996). Digital images from the EMSA radiographs were obtained using an image scanner.
- Biliverdin induces donor specific tolerance to cardiac allograft. As is shown in Figs. 8A-8C, administration of biliverdin (50 ⁇ mol/kg) using the same treatment schedule as CoPPIX, i.e., one dose per day, prolonged graft MST to 20.5 days
- Biliverdin suppresses T cell proliferation in vitro.
- na ⁇ ve B6AF1 splenocytes were stimulated with ConA, anti-CD3 mAb or irradiated DBA/2 splenocytes in the presence or absence of biliverdin.
- Biliverdin suppressed leukocyte proliferation in all cases in a dose-dependent manner (Figs. 10A-10C).
- a significant suppressive effect was achieved at concentrations of 50 ⁇ M and 100 ⁇ M for ConA or anti-CD3 mAb driven T cell proliferation and at 10 ⁇ M in the case of alloantigen mediated T cell activation (Fig. 10C).
- biliverdin appeared to act directly on T cells in that proliferation of purified B6AF1 mouse T cells (purity over 95%) in response to anti-CD3 mAb plus anti-CD28 mAb co- stimulation, a combination shown to stimulate T cells in an antigen presenting cell independent manner, was also suppressed by biliverdin (Fig. 10D).
- Biliverdin suppresses IL-2 production by blockade of nuclear translocation of NFAT and NF- ⁇ B in T cells.
- IL-2 production by splenocytes following anti-CD3 mAb stimulation was significantly suppressed in a dose-dependent manner by biliverdin treatment in vitro (Fig. 11 A).
- Addition of exogenous recombinant IL-2 (50 U/ml) into culture wells 6 or 24 hours after biliverdin treatment overcame the suppressive effect of biliverdin (Fig. 1 IB).
- biliverdin at a concentration of 100 ⁇ M did not affect the expression of the IL-2 receptor ⁇ -chain (IL-2R , CD25) of anti-CD3 mAb stimulated splenic CD4 + T cells. Representative results are shown after 6 hours of culture compared to the non-treatment control (Fig. 11C); similar results were seen after 24 hours.
- biliverdin may exert its effect on T cells by interfering directly with the signal transduction pathway leading to IL-2 synthesis, but not by down-regulation of IL-2R ⁇ surface expression or blocking the signaling pathways involved in IL-2 driven proliferation.
- NF- ⁇ B and NFAT transcription factors involved in IL-2 transcription/expression
- NF- ⁇ B and NFAT transcription factors involved in IL-2 transcription/expression
- NF- ⁇ B and NFAT transcription factors involved in IL-2 transcription/expression
- EMSA DNA-binding activity of nuclear extracts by EMSA.
- PMA plus ionomycin stimulation induced the activation of NF- ⁇ B and NFAT nuclear translocation and DNA binding, as assessed 2 and 4 hours after stimulation, respectively.
- Biliverdin inhibited DNA binding of both NF- ⁇ B and NFAT (Fig.
- Enzymatic activity of HO-1 is essential for donor splenocvte infusion (DSD mediated long-term allograft acceptance.
- DSD donor splenocvte infusion
- D-7 led 50% (4/8) of the allografts to survive for more than 100 days (Fig. 12B).
- the induction of HO-1 expression by administration of CoPPIX to the donor for 2 days (day -1 and day -2) and to the recipient from day -8 (one day before DSI) to day 6 plus DSI (D-7) allowed all of the cardiac allografts (100%, 7/7) to survive over 100 days.
- the treatment period and the dose are identical to other CoPPIX treatment protocols used in the present study.
- ferritin heavy chain (H-ferritin) gene was evaluated for potential cytoprotective effects that could be used in a therapeutic manner, e.g., to suppress ischemia reperfusion injury (IRI) of transplanted organs.
- TNF-a induced apoptosis Primary bovine aortic endothelial cells (BAEC) or murine 2F-2B EC (ATCC) were cotransfected with ⁇ -galactosidase plus control (pcDNA3 or pcDNA3/HO-l) or pcDNA3/H-Ferritin. Apoptosis was induced by TNF- ⁇ plus Act.D and quantified.
- Murine 2F-2B cells were cotransfected with ⁇ -galactosidase plus control (pcDNA3) or pcDNA3/H-ferritin and treated with etoposide (200 ⁇ M, 8h) or subjected to serum deprivation (0.1% FCS, 24 hours).
- Murine 2F-2B cells were cotransfected with ⁇ - galactosidase plus increasing amounts of pcDNA/H-ferritin (0.1-200 ng/well). As controls, pcDNA3 and pcDNA3/HO-l were used. EC apoptosis was induced by TNF- ⁇ plus Act.D, and the apoptosis of ⁇ -galactosidase-transfected EC was quantified.
- Livers were harvested from SD rats, exposed to ischemia (24 hours, 4°C, University of Wisconsin (UW) solution (Oxford Textbook of Surgery, Morris and Malt, Eds., Oxford University Press, 1994) and perfused ex vivo with syngeneic blood. Livers were transduced with recombinant adenoviras encoding H-ferritin, and controls were either non-transduced or transduced with ⁇ - galactosidase. Bile production was measured using standard methods at 30, 60, 90 and 120 minutes.
- Control EC (transfected with pcDNA3) showed 60-70%) apoptotic cells after exposure to TNF- ⁇ in the presence of the transcription inhibitor Actinomycin D (Act.D) (Fig. 13A-13C).
- Actinomycin D Actinomycin D
- Fig. 13A-13C Expression of H-ferritin suppressed TNF- ⁇ mediated EC apoptosis (10% apoptotic EC) (Fig. 13A-13C). This protective effect was observed in the EC line 2F-2B as well in primary bovine aortic EC (B AEC) (Fig. 13A).
- the anti-apoptotic effect of H-ferritin was also observed with other pro- apoptotic stimuli such as etoposide or serum deprivation (Fig. 13B).
- Recombinant adenoviras mediated H-ferritin expression protects livers from ex-vivo reperfusion injury.
- Rat livers exposed to prolonged cold ischemia UW solution, 4°C, 24 hours
- Injury was evidenced by the relative low increase in portal blood flow (from 0.63 ⁇ 0.076 ml/min g at time 0 to 1.13+0.23 at ml/min g at 120 min) and bile production (from 0.00338 ⁇ 0.0078 ml/g at time 0 to 0.025 ⁇ 0.01 ml g at 120 min)(Fig.
- H-ferritin transduced livers Unlike untreated or ⁇ -galactosidase transduced groups, H-ferritin transduced livers showed significantly (p ⁇ 0.01) greater increases in portal blood flow (from 0.62+0.099 ml/min/g at time 0 to 1.372+0.133 ml/min/g at 120 min) and bile production (from 0.00621+0.0029 ml/g at time 0 to 0.043+0.0088 at 120 min)(Fig. 14A). Further, ALT release in the H-ferritin transduced livers remained at relatively low levels (from 9.3+4.5IU/1 at time 0 to 68.6+14.8 IU/1 at 120 minutes).
- Livers transduced with the H-ferritin gene also had a significantly better preservation of their histological detail, as compared to non-transduced (p ⁇ 0.05) or ⁇ -galactosidase (p ⁇ 0.05) transduced livers, as assessed by standard Suzuki's pathological scoring.
- Recombinant adenoviras mediated H-ferritin expression prevents IRI following orthotopic liver transplantation.
- Livers from SD rats exposed to prolonged cold ischemia U.W. solution, 4°C, 24 hours
- H-ferritin By its ability to suppress liver IRI, expression of the H-ferritin gene may result in the safer use of liver transplants despite prolonged periods of cold ischemia.
- the protective effect of H-ferritin appears to be associated with its ability to inhibit endothelial cell (EC) and hepatocyte apoptosis in vivo and in vitro.
- Example 4 Enhanced Islet Graft Survival The ability of exogenously administered biliverdin or CoPP to enhance syngeneic islet transplantation was evaluated. Materials and Methods
- mice Male DBA/2, B6AF1 and DBA/1 mice 6-8 week of age (Jackson) are used in the experiments. Mice were kept for 2 weeks at 4 mice/cage and fed normal laboratory chow before using for the experiment. Treatment protocol Recipients were rendered diabetic using streptozotocin
- STZ 225 mg/kg
- mice with two consecutive blood glucose levels exceeding 350 mg/dl are used as recipients.
- Islets (500) are transplanted under the kidney capsule of the recipients.
- CoPPIX Cobalt protopo ⁇ hyrin
- biliverdin dihydrochloride ICN Biomedicals Inc., OH
- CoPPIX 20 mg/kg was given 24 hours before islet isolation to induce HO-1 expression.
- tissue samples are collected 24 hours after treatment and snap frozen in liquid nitrogen, hnmunohistological analysis of HO-1 expression is performed using an anti-HO-1 antibody.
- CoPPIX (20 mg/kg) was administrated to the recipient intraperitoneally (i.p.) on day -1, 1, 3, 5 and 7.
- Biliverdin (50 ⁇ mol/kg) or bilirabin (8.5 ⁇ mol/kg) was given intraperitoneally to the donor one hour before islet isolation.
- biliverdin (50 ⁇ mol/kg) or bilirabin (8.5umol/kg) was administered intraperitoneally either daily or twice per day from day -1 until day 13. No further treatment was given afterwards.
- Glucose levels were tested twice weekly after transplantation. Glucose levels of ⁇ 200 mg/dl were considered normoglycemic. Grafts were considered rejected when two consecutive glucose levels were >300 mg/dl. Tolerance test. The first graft was removed from a number of animals that had islets surviving long-term (longer than 100 days) by doing a nephrectomy. Islets syngeneic with the original donor were transplanted under the contralateral kidney capsule without further treatment. If those second transplanted islets also survived longer than 100 days without further treatment, the recipients were considered tolerant. Antigen-specific tolerance was assessed by transplanting islets of a third- 5 party donor (DBA/1) that does not share either class I or class II antigens with the original donor.
- DBA/1 third- 5 party donor
- H&E Hematoxylin and eosin
- insulin staining were performed on grafts that survived long-term (longer than 100 days).
- the primers for murine and human HO-1 (5': TGA AGG AGG CCA CCA 5 AGG AGG T (SEQ ID NO:l); 3': AGG TCA CCC AGG TAG CGG GT (SEQ ID NO:2)) and ⁇ -actin (525bp) (5': GCC ATC CTG CGT CTG GAC CTG G (SEQ ID NO:3); 3': TAG TCC TGC TTG CTG ATC CAC A (SEQ ID NO:4)) were obtained from LifeTechnologies, NY, USA.
- PCR reactions were performed after a 4 min denaturation at 94°C a repeating the cycle 94°C, 55°C and 72°C each for 1 min for 0 number of cycles specific for each primer pair in a Peltier Tennal Cycler PTC-200 (MJ Research, Las Vegas, NV, USA). PCR products (10-20 ⁇ l) were analyzed in an ethidium bromide-stained 1% agarose gel. Results HO-1 in allogeneic islet transplantation. When CoPP was given to the donor 5 animal, HO-1 expression was observed in several different tissues such as heart, kidney, pancreas, liver and spleen. HO-1 expression in isolated islets was verified by semi-quantitative PCR analysis.
- Islet transplantation was done from DBA 2 (H-2 d ) to B6AF1 (H-2 b a ) mice. Subsequently, HO-1 was induced with CoPP for allogeneic transplantation. HO-1 was induced in the donor from one day before taking the islets 0 and in the recipient on days -1, 1, 3, 5 and 7 with regard to transplantation. This protocol led to prolongation of survival in general but also to some islets surviving long-term (longer than 100 days) despite the absence of any treatment after day 7 after transplantation. In addition, inducing HO-1 only in the donor without treatment of the recipient led not only to prolonged survival and function of the islets in the recipient 5 but also to an occasional long-term surviving graft.
- Balloon Injury model After the exposure of the left common carotid and the left external carotid arteries, a 2F Fogarty catheter (Edwards Lifesciences LLC, Irvine, CA) was introduced via the external carotid artery and was advanced into the left common carotid artery, inflated to 2 atmospheres of pressure and pulled back to the point of bifurcation, then deflated. This procedure was repeated three times.
- a 2F Fogarty catheter Edwards Lifesciences LLC, Irvine, CA
- Biliverdin dihydrochloride (ICN Biomedicals Inc., Aurora, OH) was dissolved in a small amount of 0.2 M NaOH, subsequently adjusted to a pH of 7.4 with 1 M HCl and diluted in PBS. The stock solution was kept at -70°C until used. Light exposure was limited as much as possible.
- proximal ligation of the common carotid artery (CCA) and distal ligation of the internal carotid artery (ICA) a polyethylene catheter was introduced into the external branch of the carotid artery and the CCA was flushed. 50 ⁇ l of PBS or Biliverdin diluted in PBS at concentrations of 1 and 0.1 mM was infused and incubated for 1 hour prior to or immediately after the injury, shaded from the light. Biliverdin was removed, the CCA flushed two times with 0.9% NaCl, and blood flow was restored through the CCA and ICA.
- Biliverdin was injected intraperitoneally at a dose of 50 ⁇ mol/kg. The first dose was injected 3 hours before, the second dose immediately after the surgical procedure. Results
- Intima media ratio area, diameter
- luminal cross- sectional area narrowing were used to assess neointimal formation.
- the person in charge of histomo ⁇ hometric analysis was blinded to the treatment.
- 24 sections from each group were statistically analyzed with StatView® software version 5.0 using ANOVA.
- FIG. 18 local pre-treatment of rat carotid arteries instilling biliverdin into the common carotid artery for one hour as well as systemic treatment with biliverdin at two time points significantly inhibits neointimal formation (arrows) after balloon injury.
- Treatment with biliverdin or CoPP can significantly reduce arterial injury following balloon injury, e.g., restenosis.
- Endotoxin lipopolysaccharide/LPS; Sigma; E. coli serotype 0128:B7; 3 mg/kg, i.v.
- Endotoxin lipopolysaccharide/LPS; Sigma; E. coli serotype 0128:B7; 3 mg/kg, i.v.
- LPS lipopolysaccharide/LPS
- E. coli serotype 0128:B7 3 mg/kg, i.v.
- Biliverdin (Frontier Scientific: prepared in PBS following solubilization in NaOH) was admimstered i.p. at 50 umol/kg 17 hours prior to, one hour prior to, and eight hours after LPS administration.
- Bronchoalveolar Lavage A bronchoalveolar lavage (B AL) was performed 24 hours after LPS administration.
- Serum cytokines were measured using commercially available ELISA kits (R&D Systems Inc.) per the manufacturer's instructions. Total protein was determined via a standard Bradford assay based on a standard curve.
- BAL was performed using standard methods; briefly, a tracheostomy was performed and 8 ml (approximately 35 ml/kg) of PBS was instilled three times. Total cell count was determined as well as differential analysis of cell type and mo ⁇ hology via Diff- Quik® Fixative (American Scientific Products) staining of a sample of the lavagate. Results
- Biliverdin administration reduced levels of LPS-induced TNF-alpha (Fig. 19) as well as levels of neutrophil (Fig. 20) and protein (Fig. 21) accumulation in the airspace. Biliverdin administration also resulted in an augmentation of the anti- inflammatory cytokine, IL-10 (Fig. 22).
- Biliverdin is a potent anti-inflammatory agent, as evidenced by its ability to reduce the inflammatory effects associated with endotoxin administration in rats.
- mice Male mice (C57BL/6J) were administered biliverdin (50 umol/kg, i.p.) 16 hours and 1 hour prior to i.p. injection of a cocktail including 0.3 ug/mouse TNF- ⁇ (mouse TNF- ⁇ ; Gibco) and 250 mg/kg, i.p. D-Galactosamine (Sigma), which induces fulminant hepatitis within 6-10 hours.
- Control mice received PBS vehicle. Serum samples were taken via cardiac puncture 6-8 hours later and analyzed for alanine aminotransferase (ALT) per an ALT assay kit from Sigma Chem. Co. following the manufacturer's directions. Results
- Biliverdin reduced serum ALT levels by more than 90% as compared to vehicle treated controls (about 1000 IU/ml in control versus 100 IU/ml in treated animals). As a reference, a normal ALT level is 20-30 IU/ml.
- Biliverdin treatment is effective in reducing the liver injury and symptoms associated with hepatitis, including acute hepatitis.
- Example 8 Small Intestine Transplantation The effect of treatment with biliverdin was assessed in an animal model of small intestine transplantation. Materials and Methods.
- the graft was perfused via the aortic segment with 5 ml chilled Ringer's lactate solution, and the intestinal lumen was irrigated with 20 ml of cold saline solution containing 0.5%> neomycin-sulfate (Sigma, St. Louis, MO). End-to-side anastomoses between the graft aorta and the recipient infrarenal aorta, and between the graft portal vein and recipient vena cava, were performed with 10-0 Novafil ⁇ suture. The cold ischemic time was 1 hour. The entire recipient intestine was removed and the enteric continuity was restored by proximal and distal end-to-end intestinal anastomoses. Recipient animals were given 20 mg/day prophylactic cefamandole nafate for 3 postoperative days. Transplanted recipients were given water 3 hours after surgery, and were fed 24 hours after surgery.
- RNA extraction was performed using the guanidium-thiocyanate phenol-chloroform extraction method as described previously (Eskandari et al, Am. J. Clin. Pathol.
- RNA pellets were resuspended in RNA-secure resuspension solution (Ambion Inc., Austin, TX), followed by removal of potentially contaminating DNA by treatment with DNase I (DNA-Free Kit, Ambion Inc., Austin, TX). Equal aliquots (5 ⁇ g) of total RNA from each sample were quantified by spectrophotometry (wavelength 250 nm) and aliquoted at a concentration of 40 ng/ ⁇ l. Peak mRNA expression was quantified in duplicate by SYBR Green two-step, real-time RT-PCR. GAPDH was used as the endogenous reference.
- cDNA first-strand complementary DNA
- the reaction was incubated at 50°C for 2 min to activate the uracil N'-glycosylase and then for 12 min at 95°C to activate the Amplitaq GoldTM polymerase followed by 40 cycles of 95 °C for 15 sec and 60°C for 1 min on an ABI PRISM 7700TM Sequence Detection System (PE Applied Biosystems, Foster City, CA).
- Real-time PCR data were plotted as the ⁇ R n fluorescence signal versus the cycle number.
- An arbitrary threshold was set to the mid-linear portion of the log ⁇ R n cycle plot.
- the threshold cycle (C T ) was defined as the cycle number at which the ⁇ R n crosses this threshold.
- Quantification of mRNA expression was normalized to GAPDH and calculated relative to control using the comparative C T method (Schmittgen et al, J. Biochem. Biophys. Methods 46(l-2):69- 8, 2000).
- RT-negative controls samples containing RNA that was not reverse transcribed
- Melting curve analyses were performed for each reaction to ensure amplification of specific product.
- the primers were subjected to gel electrophoresis to confirm the absence of non-specific bands and to confirm that the amplicons were of the correct size. Efficiency of PCR-amplification of target cDNA was examined to measure colinearity of dilution.
- a segment of mid-jejunum was pinned in a SylgaardTM lined dissecting dish containing pre-oxygenated Krebs-Ringer-bicarbonate buffer (KRB; in mM: 137.4 Na + , 5.9 K + , 2.5 Ca 2+ , 1.2 Mg 2+ , 134 Cl “ , 15.5 HCO 3 " , 1.2 5 H 2 PO 4 " , and 11.5 glucose) that was equilibrated with 97% O 2 /3% C0 2 .
- the intestine was opened along the mesenteric border and the mucosa removed by stripping with fine forceps. Full-thickness strips of muscularis (1x6 mm) were cut parallel to the circular muscle layer.
- Muscle strips were mounted in standard horizontal mechanical organ chambers that were continuously superfused with pre-oxygenated KRB maintained at 37°C. One end of each strip was attached by ligature to a fixed post and the other to an isometric force transducer (WPI, Sarasota, FL). Strips were allowed to equilibrate for 1 hour, after which they were incrementally stretched to the length at which maximal spontaneous contraction occurred (L 0 ). After a second equilibration period of 30 minutes, contractility-response curves were generated by exposing the tissues to increasing concentrations of the muscarinic agonist bethanechol (0.3 to 300 ⁇ M) for 10 minutes, followed by a 10-minute wash period. Contractile activity was calculated by integrating the area under the trace, normalized by converting the weight and length of the strip to square millimeters of tissue (1.03 mg/mm 2 ), and reported as g/s/mm 2 .
- Intestinal microvascular blood flow was monitored by placing the flat probe of a laser Doppler flowmeter (BLF 21D,
- the preparation of everted gut sacs was performed in ice- cold modified Krebs-Henseleit bicarbonate buffer [KHBB (pH 7.4)] consisting of 10 mM HEPES, 137.0 mM NaCl, 5.36mM KCl, 4.17 mM NaHCO3, 0.34 mM Na2HPO4, 0.44 mM KH2P04, 0.41 mM MgSO47H20, 0.49 mM MgC126H20, 1.26 mM CaC12, and 19.45mM glucose.
- KHBB ice- cold modified Krebs-Henseleit bicarbonate buffer
- a groove was cut into the tip of a 5ml plastic syringe and 1.5 mL of KHBB was drawn into the syringe.
- the open end of the everted gut sac was secured to the groove using 4-0 silk, and the intestine was gently distended by injecting the KHBB from the syringe.
- the sac was suspended in a beaker holding 80 mL of a solution of KHBB maintained at 37°C and containing fluorescein-isothiocyanate dextran (average M.W. 4000 Da; FD4; 20mg/mL).
- the bathing solution was aerated by gently bubbling with a gas mixture containing 95% O2 and 5 % CO2.
- Serum samples from the recipients transplanted with preserved intestine were taken at 3 and 12 hours after reperfusion and stored at -80° until evaluation.
- Serum IL-6 was determined using a rat enzyme- linked immunoassay (ELISA) kits as described by the manufacturer (R & D Systems, Inc., Cambridge, MA).
- ELISA enzyme- linked immunoassay
- serum nitrite/nitrate levels were measured 12 hours after engraftment using a commercially available test kit (Cayman, Ann Arbor, MI). In this assay system, nitrate is reduced to nitrite using nitrate reductase, and the nitrite concentration of the sample is subsequently measured using the Griess reaction.
- Results are expressed as mean plus or minus the standard error of the mean (SEM). Statistical analysis was performed using Student's t test or analysis of various (ANOVA) where appropriate. A probability level of p ⁇ 0.05 was considered statistically significant.
- Serum bilirubin levels and BVR expression in the graft Serum bilirubin levels and BVR expression in the graft.
- serum bilirubin levels were analyzed. Before BV treatment, serum bilirabin levels were undetectable. Thirty minutes after BV injection i.p., serum bilirabin levels reached a peak of
- Circular muscle contractility To determine the direct effects of SITx and BV on the muscular apparatus, the effects of SITx with and without BV treatment were investigated on spontaneous and bethanechol-stimulated j ejunal circular muscle contractility using in vitro organ bath experiments. Tissues were harvested 24 hours after transplantation of the intestinal graft, a time point when intestinal motility associated with SITx is known to be maximally suppressed (Schwarz et al, Surgery 131:413-423 (2002)). Control animals treated with B V demonstrated no change in their spontaneous muscle contractile activity.
- SITx results in a significant decrease in spontaneous muscle contractile activity, however, j ejunal muscle strips harvested from grafts transplanted into recipient animals treated with BV demonstrated significantly greater spontaneous contractile activity as compared to untreated transplants.
- bethanechol 0.3 to 300 ⁇ M
- bethanechol 0.3 to 300 ⁇ M
- Control muscles from untreated and BV treated animals exhibited similar robust phasic and tonic contractions to bethanechol (100 ⁇ M), while muscles from the untreated transplanted intestine generated approximately 51% less contractility in response to bethanechol (1.7+0.4 g/mm2/s).
- MPO Myeloperoxidase
- PMN polymo ⁇ honuclear neutrophil
- BV treatment did not significantly change the upregulation of TNF- ⁇ or IL-10 caused by transplantation (Figs. 23B and 23C.
- BV treatment of unoperated animals also did not alter the basal mRNA expression of any of the cytokines.
- Gene expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX-2) were quantified by real time RT-PCR. The results showed that both iNOS and COX-2, enzymes of the baseline smooth muscle inhibitors nitric oxide and prostanoids, were significantly upregulated in the muscularis of the transplanted grafts 70.4-fold and 5.2-fold, respectively (Fig. 24A-B).
- HO-1 Induction During Intestinal LR Injury Since HO-1 regulates heme catalysis and BV production, exogenously provided BV may influence endogenous HO-1 induction in BV-freated recipients. In the normal intestine, HO-1 protein expression was absent. Ischemia/reperfusion injury was associated with a gradual increase of HO-1 expression in air-treated grafts, reaching maximum level between 6 and 24 hours following reperfusion. BV treatment did not have a significant effect on the intestinal HO-1 production. SITx with 6 hours preservation (severe injury) Antioxidant capacity after BV treatment, the total antioxidant capacity or antioxidant power within the graft specimens was quantitatively measured.
- Antioxidant levels in the graft were detected using Total Antioxidant Power® (Oxford Biomedical Research, Oxford, MI), according to the manufacturer's instractions. hi this procedure, the evaluation of the antioxidant level in a sample is detected by evaluation of Cu + derived from Cu ++ by the combined action of all antioxidants present in the sample. As is shown in Fig. 27, BV treatment increased the antioxidant capacity of the transplanted intestine to normal levels.
- Serum inflammatory mediators Serum inflammatory mediators.
- the decreased expression of IL-6 and iNOS mRNA (Figs. 23 A and 24B) was also reflected in protein production after transplantation of cold-preserved grafts; saline and BV treated controls semm IL-6 concentrations were low.
- nitric oxide As a regulator of gastrointestinal motility, the molecular expression of iNOS was followed by measuring nitric oxide metabolites in the serum of the transplanted animals, hi saline and BV freated controls, mean serum nitrite/nitrate (NO) levels were 17.3+7.4 and 18.4+3.2 ⁇ M, respectively. SITx resulted in a significant elevation of serum NO products to 34.4+15.2 ⁇ M 12 hours after engraftment. BV treatment significantly decreased transplantation-induced serum NO levels by 53 % to 18.2+3.9 ⁇ M. Graft permeability. Loss of intestinal barrier function causes increase of graft permeability.
- Graft permeability was determined by the everted gut sac method using 4Kd Fluorescein isothiocyanate dextran. A striking increase in permeability was seen in untreated grafts (1.44 ⁇ 1.0 ml/cm/min). In BV treated grafts, there was a minimal increase of intestinal permeability, or about a 60% inhibition of the increase, to 2.82+ 1.3 ml/cm/min (Fig. 26A).
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03746978A EP1499186A4 (en) | 2002-04-15 | 2003-04-15 | Use of heme oxygenase-1 and products of heme degradation |
CA002482260A CA2482260A1 (en) | 2002-04-15 | 2003-04-15 | Use of heme oxygenase-1 and products of heme degradation |
JP2003585506A JP2005522521A (en) | 2002-04-15 | 2003-04-15 | Use of heme oxygenase-1 and heme degradation products |
AU2003226366A AU2003226366A1 (en) | 2002-04-15 | 2003-04-15 | Use of heme oxygenase-1 and products of heme degradation |
US10/511,612 US8097585B2 (en) | 2002-04-15 | 2003-04-15 | Methods of treating inflammation by administration of heme oxygenase-1 and products of heme degradation |
AU2009227862A AU2009227862A1 (en) | 2002-04-15 | 2009-10-19 | Use of heme oxygenase-1 and products of heme degradation |
US13/315,791 US20120195976A1 (en) | 2002-04-15 | 2011-12-09 | Methods of treating inflammation by administration of heme oxygenase-1 and products of heme degradation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37276202P | 2002-04-15 | 2002-04-15 | |
US60/372,762 | 2002-04-15 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/315,791 Continuation US20120195976A1 (en) | 2002-04-15 | 2011-12-09 | Methods of treating inflammation by administration of heme oxygenase-1 and products of heme degradation |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003088748A1 true WO2003088748A1 (en) | 2003-10-30 |
WO2003088748A8 WO2003088748A8 (en) | 2004-01-29 |
Family
ID=29250903
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/011411 WO2003088748A1 (en) | 2002-04-15 | 2003-04-15 | Use of heme oxygenase-1 and products of heme degradation |
Country Status (6)
Country | Link |
---|---|
US (2) | US8097585B2 (en) |
EP (1) | EP1499186A4 (en) |
JP (1) | JP2005522521A (en) |
AU (2) | AU2003226366A1 (en) |
CA (1) | CA2482260A1 (en) |
WO (1) | WO2003088748A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006054757A1 (en) * | 2004-11-16 | 2006-05-26 | Astellas Pharma Inc. | Caspase inhibitor |
WO2006132583A1 (en) * | 2005-06-07 | 2006-12-14 | Innate Pharmaceuticals Ab | Method and means for preventing and inhibiting respiratory disease, atherosclerosis and osteoporosis caused by chlamydia pneumoniae infection |
WO2007073005A1 (en) * | 2005-12-22 | 2007-06-28 | Keio University | Regulator of methyl transfer reaction |
WO2008008513A2 (en) * | 2006-07-13 | 2008-01-17 | Beth Israel Deaconess Medical Center Inc. | Combination treatments |
WO2008113134A1 (en) * | 2007-03-20 | 2008-09-25 | Garvan Institute Of Medical Research | Method of transplantation of a kidney |
EP2868348A1 (en) * | 2013-11-04 | 2015-05-06 | Universität Zürich | CO-releasing compounds & formulations thereof useful for inducing mitochondrial biogenesis and tissue repair |
US9522163B2 (en) | 2002-05-17 | 2016-12-20 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods of treating hepatitis |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8128963B2 (en) * | 1996-09-27 | 2012-03-06 | The Trustees Of Columbia University In The City Of New York | Methods for treating ischemic disorders using carbon monoxide |
US7678390B2 (en) * | 1999-04-01 | 2010-03-16 | Yale University | Carbon monoxide as a biomarker and therapeutic agent |
DE60229848D1 (en) * | 2001-06-21 | 2008-12-24 | Beth Israel Hospital | - AND ORGANTRANSPLANTATIONS AND SUPPRESSING APOPTOSIS |
SG148850A1 (en) * | 2002-02-13 | 2009-01-29 | Beth Israel Hospital | Methods of treating vascular disease |
CA2481786A1 (en) * | 2002-04-15 | 2003-10-30 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Methods of treating necrotizing enterocolitis |
WO2003088748A1 (en) | 2002-04-15 | 2003-10-30 | Beth Israel Deaconess Medical Center | Use of heme oxygenase-1 and products of heme degradation |
EP1499333B1 (en) * | 2002-04-15 | 2015-06-24 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Carbon monoxide for use in a method of treating ileus |
US20040131703A1 (en) * | 2002-06-21 | 2004-07-08 | Bach Fritz H. | Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation |
AU2003283982A1 (en) * | 2002-11-07 | 2004-06-03 | University Of Pittsburgh Of The Commonwealth System Of High Education | Treatment for hemorrhagic shock |
US7504243B2 (en) * | 2004-03-19 | 2009-03-17 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for the production of biliverdin |
WO2011002584A1 (en) * | 2009-07-02 | 2011-01-06 | The University Of Iowa Research Foundation | Treatment of hepatitis c virus infections |
US8455222B2 (en) | 2009-11-04 | 2013-06-04 | Utah State University | Biliverdin from a non-animal source |
WO2014043647A1 (en) | 2012-09-14 | 2014-03-20 | Utah State University | Therapeutic compositions and associated methods |
US20140112882A1 (en) * | 2012-10-08 | 2014-04-24 | The Board Of Trustees Of The Leland Stanford Junior University | Methods to treat pancreatic inflammation and associated lung injury through regulation of pancreatic interleukin-22 expression |
EP3976636A1 (en) * | 2019-05-28 | 2022-04-06 | PreviPharma Consulting GmbH | Method for preparing iron-depleted ferritin and use thereof |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4053590A (en) | 1975-02-27 | 1977-10-11 | Alza Corporation | Compositions of matter comprising macromolecular hemoglobin |
JPS5381611A (en) | 1976-12-28 | 1978-07-19 | Kimihiko Okazaki | Hepatic medicine |
US4264739A (en) | 1979-01-05 | 1981-04-28 | Merck & Co., Inc. | Sparger for cell culture system |
JPS5679957A (en) | 1979-12-05 | 1981-06-30 | Sogo Seibutsu Igaku Kenkyusho:Kk | Erucinia enterocolitica polysaccharide sensitizing blood cell and method of detecting erucinia enterocolitica polysaccharide antibody using this |
US5240912A (en) | 1983-05-09 | 1993-08-31 | Todaro George J | Transforming growth factor (TGF) peptides |
US4979939A (en) | 1984-05-14 | 1990-12-25 | Surgical Systems & Instruments, Inc. | Atherectomy system with a guide wire |
US5084380A (en) | 1985-01-29 | 1992-01-28 | Applied Biotechnology | Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins |
US5449665A (en) | 1985-09-24 | 1995-09-12 | Item Development Aktiebolag | Continuous intravenous infusion of adenosine to human patients undergoing percutaneous transluminal angioplasty |
DE3739650C1 (en) | 1987-11-23 | 1989-05-24 | Immuno Ag | Fermenter for growing cell cultures |
US5180366A (en) | 1990-10-10 | 1993-01-19 | Woods W T | Apparatus and method for angioplasty and for preventing re-stenosis |
US5792325A (en) | 1990-11-15 | 1998-08-11 | Richardson, Jr.; William H. | Electric arc material processing system |
US5293875A (en) | 1992-06-16 | 1994-03-15 | Natus Medical Incorporated | In-vivo measurement of end-tidal carbon monoxide concentration apparatus and methods |
DE69433723T3 (en) | 1993-02-22 | 2008-10-30 | Abraxis Bioscience, Inc., Los Angeles | PROCESS FOR IN VIVO ADMINISTRATION OF BIOLOGICAL SUBSTANCES AND COMPOSITIONS USED THEREFROM |
EP0804244A1 (en) | 1993-03-26 | 1997-11-05 | Biorelease Technologies, Inc. | Compositions including heme-containing proteins and methods relating thereto |
US5523092A (en) | 1993-04-14 | 1996-06-04 | Emory University | Device for local drug delivery and methods for using the same |
US5985307A (en) | 1993-04-14 | 1999-11-16 | Emory University | Device and method for non-occlusive localized drug delivery |
US5763431A (en) | 1993-08-20 | 1998-06-09 | Jackson; Meyer B. | Method for regulating neuropeptide hormone secretion |
DE4421433C1 (en) | 1994-06-18 | 1995-06-08 | Lohmann Therapie Syst Lts | Transdermal therapeutic system for treatment of, e.g., hypertension |
US5476764A (en) | 1994-09-16 | 1995-12-19 | The Regents Of The University Of California | Method using CO for extending the useful shelf-life of refrigerated red blood cells |
CA2132690A1 (en) * | 1994-09-22 | 1996-03-23 | Dean Willis | Control and modulation of inflammatory response in humans in need of such control and modulation |
US6066333A (en) | 1994-09-22 | 2000-05-23 | William Harvey Research Limited | Pharmaceutical control of inflammation |
US5588960A (en) | 1994-12-01 | 1996-12-31 | Vidamed, Inc. | Transurethral needle delivery device with cystoscope and method for treatment of urinary incontinence |
US5664563A (en) | 1994-12-09 | 1997-09-09 | Cardiopulmonary Corporation | Pneumatic system |
US5914316A (en) | 1994-12-16 | 1999-06-22 | Washington University | Method of inhibiting intimal hyperplasia |
US5712293A (en) | 1995-06-07 | 1998-01-27 | Sepracor, Inc. | Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride |
FR2735382B1 (en) | 1995-06-15 | 1997-07-25 | Air Liquide | CARBON MONOXIDE PRODUCTION PLANT INCORPORATING A CRYOGENIC SEPARATION UNIT |
AU5938696A (en) | 1995-06-30 | 1997-02-05 | Zymogenetics Inc. | 4-(2-(n-2-carboxamidoindole)aminoethyl)-benzenesulfonamides or sulfonylureas as pdgf antagonists |
DE19535781C2 (en) | 1995-09-26 | 1999-11-11 | Fraunhofer Ges Forschung | Device for active flow support of body fluids |
ES2267141T3 (en) | 1996-04-05 | 2007-03-01 | The General Hospital Corporation | TREATMENT OF A HEMOGLOBINOPATIA. |
US6069132A (en) | 1996-08-14 | 2000-05-30 | Revanker; Ganapathi R. | Phosphazole compounds |
WO1998007447A1 (en) | 1996-08-23 | 1998-02-26 | Algos Pharmaceutical Corporation | Anticonvulsant containing composition for treating neuropathic pain |
PT921807E (en) | 1996-08-27 | 2004-04-30 | Messer Griesheim Gmbh | MEDICINES CONTAINING HYDROGEN |
US5756492A (en) * | 1996-09-09 | 1998-05-26 | Sangstat Medical Corporation | Graft survival prolongation with porphyrins |
US6315995B1 (en) | 1996-09-27 | 2001-11-13 | The Trustees Of Columbia University In The City Of New York | Methods for treating an ischemic disorder and improving stroke outcome |
ATE358492T1 (en) | 1996-09-27 | 2007-04-15 | Univ Columbia | TREATMENT OF ISCHEMIC DISORDER AND TO IMPROVE INFARCT OUTCOME |
US6316403B1 (en) | 1996-09-27 | 2001-11-13 | The Trustees Of Columbia University In The City Of New York | Methods for treating an ischemic disorder and improving stroke outcome |
US8128963B2 (en) | 1996-09-27 | 2012-03-06 | The Trustees Of Columbia University In The City Of New York | Methods for treating ischemic disorders using carbon monoxide |
US6436365B2 (en) | 1997-09-23 | 2002-08-20 | Schering Aktiengesellschaft | Process for therapeutic treatment of proliferative diseases |
US6251418B1 (en) | 1997-12-18 | 2001-06-26 | C.R. Bard, Inc. | Systems and methods for local delivery of an agent |
NZ506432A (en) | 1998-03-16 | 2003-08-29 | Celgene Corp | 2-(2,6-dioxopiperidin-3-yl) isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines |
US6450989B2 (en) | 1998-04-27 | 2002-09-17 | Artemis Medical, Inc. | Dilating and support apparatus with disease inhibitors and methods for use |
US6203991B1 (en) | 1998-08-21 | 2001-03-20 | The Regents Of The University Of Michigan | Inhibition of smooth muscle cell migration by heme oxygenase I |
WO2000036113A2 (en) | 1998-12-17 | 2000-06-22 | Sangstat Medical Corporation | Extending graft survival by heme oxygenase-i expression induced immunomodulation |
US7678390B2 (en) | 1999-04-01 | 2010-03-16 | Yale University | Carbon monoxide as a biomarker and therapeutic agent |
US20050250688A1 (en) | 1999-04-01 | 2005-11-10 | The Trustees Of Columbia University In The City Of New York | Methods for treating an ischemic disorder and improving stroke outcome |
EP1181032A4 (en) | 1999-04-14 | 2004-08-25 | Breonics Inc | System for exsanguinous metabolic support of an organ or tissue |
US7632803B2 (en) | 1999-10-01 | 2009-12-15 | Dmi Life Sciences, Inc. | Metal-binding compounds and uses therefor |
US6508784B1 (en) | 2000-05-19 | 2003-01-21 | Yan-Ho Shu | Balloon catheter having adjustable centering capabilities and methods thereof |
FR2812197B1 (en) | 2000-07-27 | 2003-01-03 | Air Liquide Sante Int | USE OF CO IN THE TREATMENT OF INFLAMMATION OF THE UPPER AIRWAYS OR BRONCHIA |
US6902881B2 (en) * | 2000-10-13 | 2005-06-07 | President And Fellows Of Harvard College | Compounds and methods for regulating cell differentiation |
FR2816212A1 (en) | 2000-11-03 | 2002-05-10 | Air Liquide Sante Int | Use of carbon monoxide to treat or prevent cardiovascular inflammation e.g. ischemia, reperfusion, stenosis, restenosis, and platelet aggregation |
US20040197271A1 (en) | 2001-03-20 | 2004-10-07 | Kunka Robert Leonard | Inhalation drug combinations |
CN1507348A (en) | 2001-03-30 | 2004-06-23 | ɣ����ҽҩ��˾ | Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders |
GB0111872D0 (en) | 2001-05-15 | 2001-07-04 | Northwick Park Inst For Medica | Therapeutic agents and methods |
WO2002096387A1 (en) | 2001-05-25 | 2002-12-05 | Medtronic, Inc. | Implantable medical device with controllable gaseous agent release system |
DE60229848D1 (en) | 2001-06-21 | 2008-12-24 | Beth Israel Hospital | - AND ORGANTRANSPLANTATIONS AND SUPPRESSING APOPTOSIS |
WO2003066067A2 (en) | 2002-02-04 | 2003-08-14 | Alfama - Investigaçao E Desenvolvimento De Produtos Farmaceuticos Lda. | Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases |
SG148850A1 (en) | 2002-02-13 | 2009-01-29 | Beth Israel Hospital | Methods of treating vascular disease |
CA2481786A1 (en) | 2002-04-15 | 2003-10-30 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Methods of treating necrotizing enterocolitis |
WO2003088748A1 (en) | 2002-04-15 | 2003-10-30 | Beth Israel Deaconess Medical Center | Use of heme oxygenase-1 and products of heme degradation |
EP1499333B1 (en) | 2002-04-15 | 2015-06-24 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Carbon monoxide for use in a method of treating ileus |
MXPA04011426A (en) | 2002-05-17 | 2005-10-19 | Univ Yale | Methods of treating hepatitis. |
UA87438C2 (en) | 2002-06-05 | 2009-07-27 | Йельский Университет | Method for treatment or prophylaxis of cancer, method for performing of surgical operation for cancer ablation and us of carbon monooxide |
US20040131703A1 (en) | 2002-06-21 | 2004-07-08 | Bach Fritz H. | Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation |
DE10230165A1 (en) | 2002-07-04 | 2004-01-15 | Ino Therapeutics Gmbh | Method and device for the administration of carbon monoxide |
AU2003283982A1 (en) | 2002-11-07 | 2004-06-03 | University Of Pittsburgh Of The Commonwealth System Of High Education | Treatment for hemorrhagic shock |
US7504243B2 (en) * | 2004-03-19 | 2009-03-17 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for the production of biliverdin |
-
2003
- 2003-04-15 WO PCT/US2003/011411 patent/WO2003088748A1/en active Application Filing
- 2003-04-15 AU AU2003226366A patent/AU2003226366A1/en not_active Abandoned
- 2003-04-15 JP JP2003585506A patent/JP2005522521A/en active Pending
- 2003-04-15 EP EP03746978A patent/EP1499186A4/en not_active Withdrawn
- 2003-04-15 US US10/511,612 patent/US8097585B2/en not_active Expired - Fee Related
- 2003-04-15 CA CA002482260A patent/CA2482260A1/en not_active Abandoned
-
2009
- 2009-10-19 AU AU2009227862A patent/AU2009227862A1/en not_active Abandoned
-
2011
- 2011-12-09 US US13/315,791 patent/US20120195976A1/en not_active Abandoned
Non-Patent Citations (6)
Title |
---|
CARRAWAY ET AL.: "Induction of ferritin and heme oxygenase-1 by endotoxin in the lung", AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, vol. 275, no. 3, September 1998 (1998-09-01), pages L583 - L592, XP002970839 * |
DATABASE BIOSIS [online] BIOLOGICAL ABSTRACTS INC., (USA); October 2002 (2002-10-01), KATORI ET AL.: "Heme oxygenase-1 systin in organ transplantation", XP002970840, Database accession no. 2002:628846 * |
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (BETHESDA, MD, USA); July 2002 (2002-07-01), SINGHAL ET AL.: "Effects of normobari hyperoxia in a rat model of focal cerebral ischemia-reperfusion", XP002970842, Database accession no. 2002393530 * |
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (BETHESDA, MD, USA); November 2001 (2001-11-01), TULIS ET AL.: "Adenovirus-mediated heme oxygenase-1 gene delivery inhibits injury-induced vascular neointima formation", XP002970841, Database accession no. 2001676797 * |
OTTERBEIN ET AL.: "Mechanism of hemoglobin-induced protection against endotoxemia in rats: a ferritin-independent pathway", AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, vol. 272, no. 2, 1997, pages L268 - L275, XP008099943 * |
See also references of EP1499186A4 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9522163B2 (en) | 2002-05-17 | 2016-12-20 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods of treating hepatitis |
WO2006054757A1 (en) * | 2004-11-16 | 2006-05-26 | Astellas Pharma Inc. | Caspase inhibitor |
WO2006132583A1 (en) * | 2005-06-07 | 2006-12-14 | Innate Pharmaceuticals Ab | Method and means for preventing and inhibiting respiratory disease, atherosclerosis and osteoporosis caused by chlamydia pneumoniae infection |
WO2007073005A1 (en) * | 2005-12-22 | 2007-06-28 | Keio University | Regulator of methyl transfer reaction |
WO2008008513A2 (en) * | 2006-07-13 | 2008-01-17 | Beth Israel Deaconess Medical Center Inc. | Combination treatments |
WO2008008513A3 (en) * | 2006-07-13 | 2008-03-06 | Beth Israel Hospital | Combination treatments |
WO2008113134A1 (en) * | 2007-03-20 | 2008-09-25 | Garvan Institute Of Medical Research | Method of transplantation of a kidney |
WO2015063258A3 (en) * | 2013-11-01 | 2015-12-17 | Universität Zürich | Co-releasing compounds & formulations thereof useful for inducing mitochondrial biogenesis and tissue repair |
EP2868348A1 (en) * | 2013-11-04 | 2015-05-06 | Universität Zürich | CO-releasing compounds & formulations thereof useful for inducing mitochondrial biogenesis and tissue repair |
Also Published As
Publication number | Publication date |
---|---|
EP1499186A1 (en) | 2005-01-26 |
EP1499186A4 (en) | 2009-10-28 |
US20060003922A1 (en) | 2006-01-05 |
JP2005522521A (en) | 2005-07-28 |
WO2003088748A8 (en) | 2004-01-29 |
US20120195976A1 (en) | 2012-08-02 |
US8097585B2 (en) | 2012-01-17 |
CA2482260A1 (en) | 2003-10-30 |
AU2003226366A1 (en) | 2003-11-03 |
AU2009227862A1 (en) | 2009-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20120195976A1 (en) | Methods of treating inflammation by administration of heme oxygenase-1 and products of heme degradation | |
AU2003279236B8 (en) | Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation | |
Nomikos et al. | Combined treatment with nicotinamide and desferrioxamine prevents islet allograft destruction in NOD mice | |
EP1499333B1 (en) | Carbon monoxide for use in a method of treating ileus | |
Ke et al. | Heme oxygenase 1 gene transfer prevents CD95/Fas ligand-mediated apoptosis and improves liver allograft survival via carbon monoxide signaling pathway | |
Cepinskas et al. | Inflammatory response in microvascular endothelium in sepsis: role of oxidants | |
Nakao et al. | Biliverdin protects the functional integrity of a transplanted syngeneic small bowel | |
SK15942003A3 (en) | Carbon monoxide improves outcomes in tissue and organ transplants apoptosis | |
Park et al. | CP-690550, a Janus kinase inhibitor, suppresses CD4+ T-cell–mediated acute graft-versus-host disease by inhibiting the interferon-γ pathway | |
CA2485465A1 (en) | Methods of treating hepatitis | |
Hou et al. | 5-Aminolevulinic acid with ferrous iron induces permanent cardiac allograft acceptance in mice via induction of regulatory cells | |
Hoffman et al. | ATTENUATION OF LETHAL GRAFT-VERSUS-HOST DISEASE BY INHIBITION OF NITRIC OXIDE SYNTHASE1 | |
Dodge et al. | Effects of donor vitamin A deficiency and pharmacologic modulation of donor T cell retinoic acid pathway on the severity of experimental graft-versus-host disease | |
EP1267881B1 (en) | USE OF MnTBAP FOR TREATING HEPATOCELLULAR INSUFFICIENCIES | |
Samlowski et al. | Nitric oxide exposure inhibits induction of lymphokine-activated killer cells by inducing precursor apoptosis | |
CN114599379A (en) | Pharmaceutical composition and kit for preventing or treating sepsis and application and treatment method thereof | |
Tamburrano | Characterization of perivascular macrophages (pvMΦ) and their contributions to post-stroke pathology | |
TW550074B (en) | Pharmaceutical composition for preventing or treating vasculopathies and chronic rejection | |
Steinbauerab et al. | I ll Extended Shock Damaged Liver Transplantation in the Rat | |
Oberley et al. | Antitumor SOD Compounds: Antitumor Activities of Compounds with Superoxide Dismutase Activity | |
Brown | Strategies to improve pancreatic islet isolation and transplantation | |
Hart-Matyas et al. | 488: The Etiology of Allograft Vasculopathy | |
Koh | T cell-mediated vascular dysfunction in human allograft arteries results from interferon-gamma dysregulation of nitric oxide synthase | |
AU2007231907A1 (en) | Methods of treating ileus | |
Bagul | The effects of erythropoietin (EPO) and carbon monoxide (CO) on renal ischaemia/reperfusion (I/R) injury in an isolated porcine kidney model |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i |
Free format text: IN PCT GAZETTE 44/2003 UNDER (81) ADD "VC" |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2482260 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003585506 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003226366 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003746978 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003746978 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006003922 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10511612 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10511612 Country of ref document: US |